{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:44:36Z","timestamp":1793295876535,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd011769","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000}}],"reference-count":634,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011769.pub2","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T01:03:30Z","timestamp":1697072610000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD)"],"prefix":"10.1002","volume":"2023","author":[{"given":"Michelle","family":"Iffland","sequence":"additional","affiliation":[{"name":"Senior Practitioner Branch; NDIS Quality and Safeguards Commission; Penrith Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuala","family":"Livingstone","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Production and Methods Directorate ; Cochrane; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikaela","family":"Jorgensen","sequence":"additional","affiliation":[{"name":"Senior Practitioner Branch; NDIS Quality and Safeguards Commission; Penrith Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Hazell","sequence":"additional","affiliation":[{"name":"Speciality of Psychiatry; University of Sydney School of Medicine; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Gillies","sequence":"additional","affiliation":[{"name":"Senior Practitioner Branch; NDIS Quality and Safeguards Commission; Penrith Australia"},{"name":"Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1365-2710.2004.00546.x","article-title":"Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial","volume":"29","author":"Akhondzadeh","year":"2004","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10578-007-0084-3","article-title":"A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder","volume":"39","author":"Akhondzadeh","year":"2008","journal-title":"Child Psychiatry and Human Development"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.pnpbp.2009.09.012","article-title":"Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism","volume":"34","author":"Akhondzadeh","year":"2010","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1089\/cap.2015.0146","article-title":"Safety and efficacy of memantine in children with autism: randomized, placebo-controlled study and open-label extension","volume":"27","author":"Aman","year":"2017","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0005|cit5","unstructured":"Study of pharmacokinetics, safety, efficacy, and tolerability of memantine in children with autism clinicaltrials.gov\/ct2\/show\/NCT00872898"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/2040-2392-3-16","article-title":"Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial","volume":"3","author":"Anagnosou","year":"2012","journal-title":"Molecular Autism"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0007|cit7","unstructured":"Intranasal oxytocin in the treatment of autism clinicaltrials.gov\/ct2\/show\/NCT00490802"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13229-021-00420-2","article-title":"Cannabinoid treatment for autism: a proof-of-concept randomized trial","volume":"12","author":"Aran","year":"2021","journal-title":"Molecular Autism"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0009|cit9","unstructured":"Cannabinoids for behavioral problems in children with ASD (CBA)"},{"issue":"10","key":"10.1002\/14651858.CD011769.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1097\/01.chi.0000231976.28719.2a","article-title":"Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial","volume":"45","author":"Arnold","year":"2006","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1089\/cap.2011.0056","article-title":"Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders","volume":"22","author":"Arnold","year":"2012","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0012|cit12","unstructured":"Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders clinicaltrials.gov\/ct2\/show\/NCT00773812"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/j.1365-2125.2012.04253.x","article-title":"Risperidone plus celecoxib in children with autistic disorder: a double-blind, randomized trial","volume":"73","author":"Akhondzadeh","year":"2012","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00213-012-2796-8","article-title":"Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial","volume":"225","author":"Asadabadi","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0015|cit15","unstructured":"Celecoxib and autism www.irct.ir\/trial\/852"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/WNF.0000000000000405","article-title":"Does pregnenolone adjunct to risperidone ameliorate irritable behavior in adolescents with autism spectrum disorder: a randomized, double-blind, placebo-controlled clinical trial?","volume":"43","author":"Ayatollahi","year":"2020","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0017|cit17","unstructured":"Efficacy of pregnenolon in treatment of irritability in teenagers with autism www.irct.ir\/trial\/32775"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1007\/s10578-020-01072-8","article-title":"Folinic acid as adjunctive therapy in treatment of inappropriate speech in children with autism: a double-blind and placebo-controlled randomized trial","volume":"52","author":"Batebi","year":"2021","journal-title":"Child Psychiatry & Human Development"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0019|cit19","unstructured":"Folinic acid in the treatment of autism spectrum disorder www.irct.ir\/trial\/35172"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/WNF.0000000000000368","article-title":"Risperidone combination therapy with propentofylline for treatment of irritability in autism spectrum disorders: a randomized, double-blind, placebo-controlled clinical trial","volume":"42","author":"Behmanesh","year":"2019","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0021|cit21","unstructured":"Effect of propentofylline in children with autism www.irct.ir\/trial\/35171"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1023\/A:1010799115457","article-title":"Lamotrigine therapy for autistic disorder: a randomised, double-blind, placebo-controlled trial","volume":"31","author":"Belsito","year":"2001","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0023|cit23","first-page":"A85","article-title":"Lamotrigine therapy for childhood autism: a randomized, double-blind, placebo-controlled trial","volume":"50","author":"Belsito","year":"1998","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13229-020-0313-1","article-title":"Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up","volume":"11","author":"Bernaerts","year":"2020","journal-title":"Molecular Autism"},{"issue":"10","key":"10.1002\/14651858.CD011769.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"S349","DOI":"10.1016\/j.biopsych.2017.02.589","article-title":"The effects of four weeks of intranasal oxytocinon social responsiveness and repetitive and restricted behaviors in autism spectrum disorders: a randomized controlled trial","volume":"81","author":"Bernaerts","year":"2020","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0026|cit26","unstructured":"Oxytocin-based pharmacotherapy for autism spectrum disorders: Investigating the neural and behavioral effects of a promising intervention approach https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2014-000586-45"},{"issue":"11","key":"10.1002\/14651858.CD011769.pub2-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/0006-3223(92)90156-T","article-title":"The use of adrenocorticotrophic hormone (4-9) analog ORG 2766 in autistic children: effects on the organization of behavior","volume":"31","author":"Buitelaar","year":"1992","journal-title":"Biological Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/BF02216053","article-title":"Behavioral effects of Org 2766, a synthetic analog of the adrenocorticotrophic hormone (4\u20139), in 14 outpatient autistic children","volume":"20","author":"Buitelaar","year":"1990","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/00004583-198807000-00010","article-title":"Efficacy and safety of fenfluramine in autistic children","volume":"27","author":"Campbell","year":"1988","journal-title":"Journal of the American Academy of Child & Adolescent Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1097\/00004583-199311000-00024","article-title":"Naltrexone in autistic children: behavioral symptoms and attentional learning","volume":"32","author":"Campbell","year":"1993","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0031|cit31","first-page":"203","article-title":"Naltrexone plasma levels, clinical response and effect on weight in autistic children","volume":"30","author":"Gonzalez","year":"1994","journal-title":"Psychopharmacology Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1023\/A:1015493412224","article-title":"Double-blind placebo-controlled trial of secretin: effects on aberrant behavior in children with autism","volume":"32","author":"Carey","year":"2002","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1007\/s10803-018-3703-x","article-title":"A randomized, placebo-controlled, blinded, crossover, pilot study of the effects of dextromethorphan\/quinidine for the treatment of neurobehavioral symptoms in adults with autism","volume":"50","author":"Chez","year":"2020","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jpeds.2015.11.033","article-title":"Efficacy of low-dose buspirone for restricted and repetitive behavior in young children with autism spectrum disorder: a randomized trial","volume":"170","author":"Chugani","year":"2016","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0035|cit35","unstructured":"Buspirone in the treatment of 2-6 year old children with autistic disorder (B-ACE)"},{"issue":"15","key":"10.1002\/14651858.CD011769.pub2-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/j.scib.2021.01.008","article-title":"Improved symptoms following bumetanide treatment in children aged 3-6 years with autism spectrum disorder: a randomized, double-blind, placebo-controlled trial","volume":"66","author":"Dai","year":"2021","journal-title":"Science Bulletin"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0037|cit37","unstructured":"A study of bumetanide for the treatment of autism spectrum disorders (first received 15 May 2017)"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/01.jcp.0000177667.35016.e9","article-title":"Tetrahydrobiopterin in the treatment of children with autistic disorder: a double-blind placebo-controlled crossover study","volume":"25","author":"Danfors","year":"2005","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD011769.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1007\/s00213-018-5010-9","article-title":"Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study","volume":"235","author":"Danforth","year":"2018","journal-title":"Psychopharmaology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0040|cit40","unstructured":"Phase 2 pilot safety study of MDMA-assisted therapy for socail anxiety in autistic adults"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0041|cit41","unstructured":"Efficacy Of N-acetyl cysteine in autism: a double-blind, placebo-controlled randomised trial www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=320918"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"474","DOI":"10.3109\/13668250.2017.1413079","article-title":"Does N-acetylcysteine improve behaviour in children with autism?: a mixed-methods analysis of the effects of N-acetylcysteine","volume":"44","author":"Dean","year":"2019","journal-title":"Journal of Intellectual & Developmental Disability"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0004867416652735","article-title":"A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder","volume":"51","author":"Dean","year":"2017","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/phar.2271","article-title":"Pharmacotherapy of autism spectrum disorder: results from the randomized BAART clinical trial","volume":"39","author":"DeVane","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0045|cit45","unstructured":"Biomarkers in autism of aripiprazole and risperidone treatment (BAART) clinicaltrials.gov\/ct2\/show\/NCT01333072"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/BF01046402","article-title":"Amisulpride versus bromocriptine in infantile autism: a controlled crossover comparative study of two drugs with opposite effects on dopaminergic function","volume":"22","author":"Dollfus","year":"1992","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"5-6","key":"10.1002\/14651858.CD011769.pub2-BIB0047|cit47","first-page":"300","article-title":"Pharmacoclinical study of an agonist and an antagonist of dopamine in early infantile autism","volume":"40","author":"Dollfus","year":"1992","journal-title":"Neuropsychiatrie de l'Enfance et de l'Adolescence"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"e10596","DOI":"10.5812\/ijpbs.10596","article-title":"Assessment the efficacy of atomoxetine in autism spectrum disorders: a randomized, double-blind, placebo-controlled trial","volume":"12","author":"Eslamzadeh","year":"2018","journal-title":"Iranian Journal of Psychiatry and Behavioral Sciences"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0049|cit49","unstructured":"Assessment the efficacy of atomoxetin(stramox) in autism spectrum disorders 6-17 years old www.irct.ir\/trial\/22109"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0050|cit50","first-page":"77","article-title":"A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism","volume":"53","author":"Fankhauser","year":"1992","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4088\/JCP.13m08500","article-title":"A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder","volume":"75","author":"Findling","year":"2014","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0052|cit52","unstructured":"Phase IV long-term maintenance study of aripiprazole in the treatment of irritability associated with autistic disorder https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01227668?term=NCT01227668&draw=2&rank=1"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1017\/S1461145712000880","article-title":"Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial","volume":"16","author":"Ghaleiha","year":"2013","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0054|cit54","unstructured":"A double-blind placebo-controlled trial of memantine added to risperidone in patients with autistic disorder https:\/\/www.irct.ir\/trial\/860"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40272-013-0036-2","article-title":"Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial","volume":"15","author":"Ghaleiha","year":"2013","journal-title":"Pediatric Drugs"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0056|cit56","unstructured":"Riluzole in the treatment of autism en.irct.ir\/trial\/877"},{"issue":"7","key":"10.1002\/14651858.CD011769.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1177\/0269881113508830","article-title":"Galantamine efficacy and tolerability as an augmentative therapy in autistic children: a randomized, double-blind, placebo-controlled trial","volume":"28","author":"Ghaleiha","year":"2014","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0058|cit58","unstructured":"Galantamine in the treatment of autism en.irct.ir\/trial\/890"},{"issue":"1-2","key":"10.1002\/14651858.CD011769.pub2-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.psychres.2015.07.043","article-title":"A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: effects on aberrant behavior in children with autism","volume":"229","author":"Ghaleiha","year":"2015","journal-title":"Psychiatry Research"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0060|cit60","unstructured":"Pioglitazone in the treatment of autism en.irct.ir\/trial\/887"},{"issue":"9","key":"10.1002\/14651858.CD011769.pub2-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1089\/cap.2015.0175","article-title":"Minocycline as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind placebo-controlled trial","volume":"26","author":"Ghaleiha","year":"2016","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0062|cit62","unstructured":"Minocycline in the treatment of autism en.irct.ir\/trial\/900"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/1471-244X-13-196","article-title":"A randomized double blind placebo controlled clinical trial of N-acetylcysteine added to risperidone for treating autistic disorders","volume":"13","author":"Ghanizadeh","year":"2013","journal-title":"BMC Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0064|cit64","unstructured":"N-acetylcysteine augmentation with risperidone in treatment of autism in children www.irct.ir\/trial\/4085"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10578-013-0390-x","article-title":"A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial","volume":"45","author":"Ghanizadeh","year":"2014","journal-title":"Child Psychiatry and Human Development"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0066|cit66","unstructured":"Aripiprazole versus risperidone for treatment of autism www.irct.ir\/trial\/4094"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.pediatrneurol.2014.09.017","article-title":"A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism","volume":"52","author":"Ghanizadeh","year":"2015","journal-title":"Pediatric Neurology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0068|cit68","unstructured":"A randomized double blind placebo controlled clinical trial of buspirone for treating autism spectrum disorders www.irct.ir\/trial\/4107"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1176\/ajp.149.3.363","article-title":"Differential response of seven subjects with autistic disorder to clomipramine and desipramine","volume":"149","author":"Gordon","year":"1992","journal-title":"American Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1001\/archpsyc.1993.01820180039004","article-title":"A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder","volume":"50","author":"Gordon","year":"1993","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0071|cit71","unstructured":"A course of oxytocin nasal spray (OT) to treat social problems in youth with autism spectrum disorders www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=83655"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/jcpp.12305","article-title":"The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial","volume":"56","author":"Guastella","year":"2015","journal-title":"Journal of Child Psychology and Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD011769.pub2-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/jir.12512","article-title":"A controlled trial of sertraline in children 2 to 6 with ASD without fragile X syndrome","volume":"62","author":"Hagerman","year":"2018","journal-title":"Journal of Intellectual Disability Research"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0074|cit74","unstructured":"A trial of sertraline in young children with autism spectrum disorder (Sert2) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02385799?term=NCT02385799&draw=2&rank=1"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"810","DOI":"10.3389\/fpsyt.2019.00810","article-title":"A randomized controlled trial of sertraline in young children with autism spectrum disorder","volume":"10","author":"Potter","year":"2019","journal-title":"Frontiers in Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1089\/cap.2017.0026","article-title":"L-carnosine as an adjunctive therapy to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial","volume":"28","author":"Hajizadeh-Zaker","year":"2018","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0077|cit77","unstructured":"L carnosine in the treatment of autism www.irct.ir\/trial\/932"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10882-005-3682-7","article-title":"Secretin in children with autistic disorder: a double-blind, placebo-controlled trial","volume":"17","author":"Handen","year":"2005","journal-title":"Journal of Developmental and Physical Disabilities"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/DBP.0b013e3181739b9d","article-title":"Guanfacine in children with autism and\/or intellectual disabilities","volume":"29","author":"Handen","year":"2008","journal-title":"Journal of Developmental & Behavioral Pediatrics"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0080|cit80","first-page":"125","article-title":"Safety and efficacy of donepezil in children - behavioural measures","volume":"2","author":"Handen","year":"2010","journal-title":"International public health journal"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1089\/cap.2010.0024","article-title":"Safety and efficacy of donepezil in children and adolescents with autism: neuropsychological measures","volume":"21","author":"Handen","year":"2011","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD011769.pub2-BIB0082|cit82","first-page":"50S","article-title":"Preliminary findings from a double-blind placebo=controlled study of donepezil in pervasive developmental disorders","volume":"59","author":"Hardan","year":"2006","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0083|cit83","unstructured":"Donepezil HCl and cognitive deficits in autism https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00047697?term=NCT00047697&draw=2&rank=1"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1089\/cap.2017.0134","article-title":"A 1.5-year follow-up of parent training and atomoxetine for attention-deficit\/hyperactivity disorder symptoms and noncompliant\/disruptive behavior in autism","volume":"28","author":"Arnold","year":"2018","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD011769.pub2-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.jaac.2015.08.013","article-title":"Atomoxetine, parent training, and their combination in children with autism spectrum disorder and attention-deficit\/hyperactivity disorder","volume":"54","author":"Handen","year":"2015","journal-title":"Journal of the American Academy of Child & Adolescent Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/s10803-017-3345-4","article-title":"Parent stress in a randomized clinical trial of atomoxetine and parent training for children with autism spectrum disorder","volume":"48","author":"Lecavalier","year":"2018","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0087|cit87","unstructured":"Atomoxetine, placebo and parent management training in autism (Strattera) clinicaltrials.gov\/ct2\/show\/NCT00844753"},{"issue":"10","key":"10.1002\/14651858.CD011769.pub2-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.jaac.2016.06.015","article-title":"Atomoxetine and parent training for children with autism and attention-deficit\/hyperactivity disorder: a 24-week extension study","volume":"55","author":"Smith","year":"2016","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD011769.pub2-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1089\/cap.2016.0187","article-title":"Adverse events of atomoxetine in a double-blind placebo-controlled study in children with autism","volume":"27","author":"Tumuluru","year":"2017","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"10","key":"10.1002\/14651858.CD011769.pub2-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"S325","DOI":"10.1016\/j.jaac.2016.07.369","article-title":"Psychopharmacological treatment of anxiety symptoms in autism spectrum disorder","volume":"55","author":"Hardan","year":"2016","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD011769.pub2-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/\/j.biopsych.2012.01.014","article-title":"A randomised controlled pilot trial of N-acetylcysteine in children with autism","volume":"71","author":"Hardan","year":"2012","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0092|cit92","unstructured":"A double-blind, placebo-controlled, randomized withdrawal study of the safety and efficacy of memantine in pediatric patients with autism, Asperger\u2019s disorder, or pervasive developmental disorder not otherwise specified (PDD-NOS) previously treated with memantine www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-001568-31\/results"},{"issue":"8","key":"10.1002\/14651858.CD011769.pub2-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1177\/1362361318824103","article-title":"Efficacy and safety of memantine in children with autism spectrum disorder: results from three phase 2 multicenter studies","volume":"23","author":"Hardan","year":"2019","journal-title":"Autism"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0094|cit94","unstructured":"Withdrawal study of memantine in pediatric patients with autism, Asperger's disorder, or pervasive developmental disorder not otherwise specified previously treated with memantine clinicaltrials.gov\/ct2\/show\/results\/NCT01592747"},{"issue":"9","key":"10.1002\/14651858.CD011769.pub2-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1089\/cap.2014.0026","article-title":"Atomoxetine in autism spectrum disorder: no effects on social functioning; some beneficial effects on stereotyped behaviours; inappropriate speech and fear of change","volume":"24","author":"Harfterkamp","year":"2014","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"S216","DOI":"10.1007\/s00787-013-0423-9","article-title":"Randomized double-blind study of atomoxetine vs. placebo followed by an open label extension period of treatment with atomoxetine for ADHD symptoms in children with ASD","volume":"22","author":"Harfterkamp","year":"2013","journal-title":"European Child and Adolescent Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD011769.pub2-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jaac.2012.04.011","article-title":"A randomized double-blind study of atomoxetine versus placebo for attention-deficit\/hyperactivity disorder symptoms in children with autism spectrum disorder","volume":"51","author":"Harfterkamp","year":"2012","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0098|cit98","unstructured":"Atomoxetine versus placebo for symptoms of attention-deficit\/hyperactivity disorder (ADHD) in children and adolescents with autism spectrum disorder clinicaltrials.gov\/ct2\/show\/NCT00380692"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1089\/cap.2005.15.682","article-title":"A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders","volume":"15","author":"Hellings","year":"2005","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/jcpt.13076","article-title":"Resveratrol as adjunctive therapy in treatment of irritability in children with autism: a double-blind and placebo-controlled randomized trial","volume":"45","author":"Hendouei","year":"2020","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0101|cit101","unstructured":"Resveratrol in treatment of autism www.irct.ir\/trial\/28378"},{"issue":"9","key":"10.1002\/14651858.CD011769.pub2-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1007\/s10803-019-04120-y","article-title":"The SOFIA Study: negative multi\u2011center study of low dose fluoxetine on repetitive behaviors in children and adolescents with autistic disorder","volume":"50","author":"Herscu","year":"2020","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0103|cit103","unstructured":"Study of fluoxetine in autism (SOFIA) clinicaltrials.gov\/ct2\/show\/NCT00515320"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1017\/S1748232105000108","article-title":"Liquid fluoxetine versus placebo for repetitive behaviors in childhood autism","volume":"1","author":"Hollander","year":"2006","journal-title":"Progress in Neurotherapeutics and Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/sj.npp.1300627","article-title":"A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviours in childhood and adolescent autism","volume":"30","author":"Phillips","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0106|cit106","unstructured":"Randomized study of fluoxetine in children and adolescents with autism clinicaltrials.gov\/ct2\/show\/NCT00004486"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1017\/S1461145705005791","article-title":"Divalproex sodium vs placebo in the treatment of repetitive behaviours in autism spectrum disorder","volume":"9","author":"Hollander","year":"2006","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0108|cit108","unstructured":"Divalproex sodium versus placebo in childhood\/adolescent autism https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00211757?term=NCT00211757&draw=2&rank=1"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1089\/cap.2006.16.541","article-title":"A double-blind placebo-controlled pilot study of olanzapine in childhood\/adolescent pervasive developmental disorder","volume":"16","author":"Hollander","year":"2006","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0110|cit110","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.1016\/S0924-977X(06)80088-X","article-title":"Divalproex sodium vs placebo for the treatment of child and adolescent autism","volume":"16","author":"Anagnostou","year":"2006","journal-title":"European Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/npp.2009.202","article-title":"Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders","volume":"35","author":"Hollander","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1017\/S1461145705005791","article-title":"Divalproex sodium vs placebo in the treatment of repetitive behaviours in autism spectrum disorder","volume":"9","author":"Hollander","year":"2006","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0113|cit113","unstructured":"Divalproex sodium vs. placebo in childhood\/adolescent autism https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00211757?term=NCT00211757&draw=1&rank=1"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1176\/appi.ajp.2011.10050764","article-title":"A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders","volume":"169","author":"Hollander","year":"2012","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0115|cit115","unstructured":"Randomized study of fluoxetine in children and adolescents with autism https:\/\/clinicaltrials.gov\/show\/NCT00004486"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"S723","DOI":"10.1016\/S0924-977X(14)71165-4","article-title":"P.7.d.006 Trichuris suis ova (TSO) as an immune-inflammatory treatment for repetitive behaviors in autism spectrum disorders (ASD)","volume":"24","author":"Hollander","year":"2014","journal-title":"European Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/15622975.2018.1523561","article-title":"Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder","volume":"21","author":"Hollander","year":"2020","journal-title":"World Journal of Biological Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0118|cit118","doi-asserted-by":"publisher","first-page":"S391","DOI":"10.1038\/npp.2013.280","article-title":"Trichuris suis ova (TSO) as an immune inflammatory treatment for repetitive behaviors in ASD","volume":"38","author":"Hollander","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/15622975.2018.1523561","article-title":"Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder","volume":"21","author":"Hollander","year":"2020","journal-title":"World Journal of Biological Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0120|cit120","unstructured":"Trichuris suis ova in autism spectrum disorders (TSO) www.clinicaltrials.gov\/ct2\/show\/NCT01040221"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1016\/j.euroneuro.2020.09.110","article-title":"Paediatric dosing of balovaptan for the treatment of the core symptoms of autism spectrum disorder: data from a Phase 2 study (aV1ation; NCT02901431)","volume":"40","author":"Stark","year":"2020","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41386-021-01236-7","article-title":"A phase 2 randomized controlled trial (RCT) of balovaptan (BAL) in pediatric participants with autism spectrum disorder (ASD)","volume":"46","author":"Hollander","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1002\/14651858.CD011769.pub2-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"S262","DOI":"10.1016\/j.jaac.2020.08.458","article-title":"Phase 2 randomized controlled trial of balovaptan in pediatric participants with autism spectrum disorder","volume":"59","author":"Hollander","year":"2020","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0124|cit124","unstructured":"A study to investigate the efficacy and safety of balovaptan (RO5285119) in participants with autism spectrum disorder (ASD) www.clinicaltrials.gov\/ct2\/show\/NCT02901431?term=NCT02901431&draw=2&rank=1"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s10578-016-0704-x","article-title":"Aripiprazole in the treatment of irritability in children and adolescents with autism spectrum disorder in Japan: a randomized, double-blind, placebo-controlled study","volume":"48","author":"Ichikawa","year":"2017","journal-title":"Child Psychiatry & Human Development"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0126|cit126","unstructured":"A short treatment study of aripiprazole in pediatric patients with autistic disorder clinicaltrials.gov\/ct2\/show\/NCT01617447"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S2215-0366(21)00429-6","article-title":"Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial","volume":"9","author":"Jacob","year":"2022","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD011769.pub2-BIB0128|cit128","doi-asserted-by":"publisher","first-page":"S163","DOI":"10.1016\/j.jaac.2020.08.108","article-title":"Phase three randomised controlled trial of balovaptan in adults with autism spectrum disorder","volume":"59","author":"Jacob","year":"2020","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0129|cit129","unstructured":"A study of balovaptan in adults with autism spectrum disorder with a 2-year open-label extension clinicaltrials.gov\/ct2\/show\/NCT03504917?term=NCT03504917&draw=2&rank=1"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00004714-199210000-00005","article-title":"Clonidine treatment of hyperactive and impulsive children with autistic disorder","volume":"12","author":"Jaselskis","year":"1992","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD011769.pub2-BIB0131|cit131","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s10803-012-1723-5","article-title":"Risperidone dosing in children and adolescents with autistic disorder: a double-blind placebo-controlled study","volume":"43","author":"Kent","year":"2013","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0132|cit132","unstructured":"A study of the effectiveness and safety of two doses of risperidone in the treatment of children and adolescents with autistic disorder clinicaltrials.gov\/ct2\/show\/NCT00576732"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0133|cit133","unstructured":"Palmitoylethanolamide as adjunctive treatment of autism: a double blind and placebo controlled trial en.irct.ir\/trial\/945"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0134|cit134","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jpsychires.2018.04.022","article-title":"Palmitoylethanolamide as adjunctive therapy for autism: efficacy and safety results from a randomized controlled trial","volume":"103","author":"Khalaj","year":"2018","journal-title":"Journal of Psychiatric Research"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0135|cit135","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1097\/00004583-200106000-00010","article-title":"Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder","volume":"40","author":"King","year":"2001","journal-title":"Journal of the American Academy of Child & Adolescent Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1001\/archgenpsychiatry.2009.30","article-title":"Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism","volume":"66","author":"King","year":"2009","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0137|cit137","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1136\/ebmh.13.1.22","article-title":"Citalopram not effective for repetitive behavior in autistic spectum disorders","volume":"13","author":"Myers","year":"2010","journal-title":"Evidence-Based Mental Health"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0138|cit138","unstructured":"Citalopram for children with autism and repetitive behavior (STAART Study 1) clinicaltrials.gov\/ct2\/show\/NCT00086645"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0139|cit139","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s10803-011-1251-8","article-title":"Design and subject characteristics in the federally-funded citalopram trial in children with pervasive developmental disorders","volume":"42","author":"Scahill","year":"2012","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0140|cit140","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1089\/cap.2012.0127","article-title":"Tetrahydrobiopterin as a treatment for autism spectrum disorders: a double-blind, placebo-controlled trial","volume":"13","author":"Klaiman","year":"2013","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0141|cit141","unstructured":"Sapropterin as a treatment for autistic disorder https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00850070?term=NCT00850070&draw=2&rank=1"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0142|cit142","unstructured":"The effects of chronic intranasal oxytocin combined with positive social interaction in the treatment of young children with autism www.chictr.org.cn\/showproj.aspx?proj=39640"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1159\/000524543","article-title":"Infrequent intranasal oxytocin followed by positive social interaction improves symptoms in autistic children: a pilot randomized clinical trial","volume":"91","author":"Le","year":"2022","journal-title":"Psychotherapy and Psychosomatics"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0144|cit144","doi-asserted-by":"publisher","first-page":"e1056","DOI":"10.1038\/tp.2017.10","article-title":"Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders","volume":"7","author":"Lemonnier","year":"2017","journal-title":"Translational Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0145|cit145","unstructured":"Efficiency of bumetanide in autistic children (BUMEA) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01078714?term=NCT01078714&draw=1&rank=1"},{"issue":"8","key":"10.1002\/14651858.CD011769.pub2-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1136\/adc.88.8.731","article-title":"Children with autistic spectrum disorders. I: comparison of placebo and single dose of human synthetic secretin","volume":"88","author":"Levy","year":"2003","journal-title":"Archives of Disease in Childhood"},{"issue":"8","key":"10.1002\/14651858.CD011769.pub2-BIB0147|cit147","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1007\/s10803-018-3536-7","article-title":"An exploratory trial of transdermal nicotine for aggression and irritability in adults with autism spectrum disorder","volume":"48","author":"Lewis","year":"2018","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0148|cit148","unstructured":"Nicotinic cholinergic modulation as a novel treatment strategy for aggression associated with autism clinicaltrials.gov\/ct2\/show\/NCT02552147"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0149|cit149","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s10803-015-2628-x","article-title":"Lurasidone for the treatment of irritability associated with autistic disorder","volume":"46","author":"Loebel","year":"2016","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0150|cit150","unstructured":"Lurasidone pediatric autism study https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01911442?term=NCT01911442&draw=2&rank=1"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0151|cit151","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1089\/cap.2006.16.575","article-title":"Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy","volume":"16","author":"Luby","year":"2006","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0152|cit152","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/00004703-200104000-00001","article-title":"Differential response of operant self-Injury to pharmacologic versus behavioral treatment","volume":"22","author":"Mace","year":"2001","journal-title":"Journal of Developmental & Behavioral Pediatrics"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0153|cit153","unstructured":"Baclofen in the treatment of autism www.irct.ir\/trial\/944"},{"issue":"12","key":"10.1002\/14651858.CD011769.pub2-BIB0154|cit154","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1007\/s00787-019-01333-5","article-title":"Baclofen as an adjuvant therapy for autism: a randomized, double-blind, placebo-controlled trial","volume":"28","author":"Saghazadeh","year":"2019","journal-title":"European Child & Adolescent Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0155|cit155","unstructured":"Prednisolone in autism spectrum disorders www.irct.ir\/trial\/28026"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0156|cit156","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/WNF.0000000000000382","article-title":"Prednisolone as adjunctive treatment to risperidone in children with regressive type of autism spectrum disorder: a randomized, placebo-controlled trial","volume":"43","author":"Malek","year":"2020","journal-title":"Clinical Neuropharmacology"},{"issue":"8","key":"10.1002\/14651858.CD011769.pub2-BIB0157|cit157","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1097\/00004583-200108000-00009","article-title":"Olanzapine versus haloperidol in children with autistic disorder: an open pilot study","volume":"40","author":"Malone","year":"2001","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0158|cit158","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11920-010-0172-0","article-title":"Aripiprazole to treat irritability associated with autism: a placebo-controlled, fixed-dose trial","volume":"13","author":"Benton","year":"2011","journal-title":"Current Psychiatric Reports"},{"issue":"9","key":"10.1002\/14651858.CD011769.pub2-BIB0159|cit159","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2165\/11208280-000000000-00000","article-title":"Aripiprazole in the treatment of irritability associated with autistic disorder in paediatric patients: profile report","volume":"25","author":"Curran","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0160|cit160","first-page":"S110","article-title":"Efficacy and safety of fixed-dose aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years)","volume":"66","author":"Lewis","year":"2009","journal-title":"Annals of Neurology"},{"issue":"8","key":"10.1002\/14651858.CD011769.pub2-BIB0161|cit161","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1089\/cap.2012.0075","article-title":"Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change","volume":"23","author":"Mankosky","year":"2013","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD011769.pub2-BIB0162|cit162","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","article-title":"A placebo-controlled, fixed-dose aripiprazole in children and adolescents with irritability associated with autistic disorder","volume":"48","author":"Marcus","year":"2009","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0163|cit163","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.clinthera.2012.02.023","article-title":"Effect of aripiprazole 2 to 15 mg\/day on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post-hoc analysis of two controlled trials","volume":"34","author":"Varni","year":"2012","journal-title":"Clinical Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0164|cit164","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1089\/cap.2015.0005","article-title":"Tolerability, safety, and benefits of risperidone in children and adolescents with autism: 21-month follow-up after 8-week placebo-controlled trial","volume":"25","author":"Aman","year":"2015","journal-title":"Journal of Child & Adolescent Psychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0165|cit165","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1089\/cap.2005.15.869","article-title":"Acute and long-term safety and tolerability of risperidone in children with autism","volume":"15","author":"Aman","year":"2005","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0166|cit166","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1089\/cap.2007.0133","article-title":"Cognitive effects of risperidone in children with autism and irritable behavior","volume":"18","author":"Aman","year":"2008","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0167|cit167","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1023\/a:1005451304303","article-title":"Assessment in multisite randomized clinical trials of patients with autistic disorder: the Autism RUPP Network. Research Units on Pediatric Psychopharmacology","volume":"30","author":"Arnold","year":"2000","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0168|cit168","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1089\/cap.2009.0022","article-title":"Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability","volume":"20","author":"Arnold","year":"2010","journal-title":"Journal of Child & Adolescent Psychopharmacology"},{"issue":"12","key":"10.1002\/14651858.CD011769.pub2-BIB0169|cit169","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1097\/00004583-200312000-00011","article-title":"Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials","volume":"42","author":"Arnold","year":"2003","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD011769.pub2-BIB0170|cit170","first-page":"915","article-title":"Risperidone improves behavior in children with autism","volume":"51","author":"Caicedo","year":"2002","journal-title":"Journal of Family Practice"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0171|cit171","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/ebmh.9.1.6","article-title":"Risperidone improves restricted, repetitive, and stereotyped behaviour in autistic children and adolescents","volume":"9","author":"Fombonne","year":"2006","journal-title":"Evidence-Based Mental Health"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0172|cit172","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.eurpsy.2015.11.004","article-title":"Initial severity and efficacy of risperidone in autism: results from the RUPP trial","volume":"32","author":"Levine","year":"2016","journal-title":"European Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0173|cit173","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/NEJMoa013171","article-title":"Risperidone in children with autism and serious behavioural problems","volume":"347","author":"McCracken","year":"2002","journal-title":"New England journal of medicine"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0174|cit174","doi-asserted-by":"publisher","first-page":"S327","DOI":"10.1016\/S0924-977X(03)92062-1","article-title":"A double-blind placebo-controlled trial of risperidone in autistic disorder","volume":"13","author":"McDougle","year":"2003","journal-title":"European Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0175|cit175","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1176\/appi.ajp.162.6.1142","article-title":"Risperidone for the core symptom domains of autism: results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology","volume":"16","author":"McDougle","year":"2005","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0176|cit176","unstructured":"Treatment of autism in children and adolescents www.clinicaltrials.gov\/ct2\/show\/NCT00005014"},{"issue":"7","key":"10.1002\/14651858.CD011769.pub2-BIB0177|cit177","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1176\/appi.ajp.162.7.1361","article-title":"Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months","volume":"162","author":"Research Units on Pediatric Psychopharmacology Autism Network","year":"2005","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0178|cit178","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s10803-012-1689-3","article-title":"Brief report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials","volume":"43","author":"Scahill","year":"2013","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0179|cit179","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1744-6171.2007.00112.x","article-title":"Risperidone approved for the treatment of serious behavioral problems in children with autism","volume":"20","author":"Scahill","year":"2007","journal-title":"Journal of Child & Adolescent Psychiatric Nursing"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0180|cit180","unstructured":"Study of risperidone with autistic children finds no detrimental cognitive effects Brown University Child & Adolescent Psychopharmacology Update 2008 10 9 3 10.1002\/cpu.20075"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0181|cit181","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/01.chi.0000196423.80717.32","article-title":"Risperidone and adaptive behavior in children with autism","volume":"45","author":"Williams","year":"2006","journal-title":"Journal of the American Academy of Child & Adolescent Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0182|cit182","first-page":"1375","article-title":"Fluvoxamine for the treatment of autistic disorders in adults","volume":"55","author":"Huffman","year":"1997","journal-title":"American Family Physician"},{"issue":"11","key":"10.1002\/14651858.CD011769.pub2-BIB0183|cit183","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1001\/archpsyc.1996.01830110037005","article-title":"A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder","volume":"53","author":"McDougle","year":"1996","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0184|cit184","volume-title":"A double-blind placebo-controlled study of fluvoxamine in treating the symptoms of autism [Master's thesis]","author":"Vegso","year":"1995"},{"issue":"7","key":"10.1002\/14651858.CD011769.pub2-BIB0185|cit185","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/archpsyc.55.7.633","article-title":"A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders","volume":"55","author":"McDougle","year":"1998","journal-title":"Archives of General Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0186|cit186","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13229-015-0062-8","article-title":"A randomized, placebo-controlled trial of D-cycloserine for the enhancement of social skills training in autism spectrum disorders","volume":"7","author":"Minshawi","year":"2016","journal-title":"Molecular Autism"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0187|cit187","unstructured":"D-cycloserine and social skills training in autism spectrum disorders https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01086475?term=NCT01086475&draw=1&rank=1"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0188|cit188","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13229-017-0116-1","article-title":"D-cycloserine enhances durability of social skills training in autism spectrum disorder","volume":"8","author":"Wink","year":"2017","journal-title":"Molecular Autism"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0189|cit189","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00787-007-0620-5","article-title":"Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial","volume":"17","author":"Miral","year":"2008","journal-title":"European Child & Adolescent Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0190|cit190","unstructured":"Simvastatin added to risperidone in the treatment of autism: a double blind and placebo controlled trial https:\/\/www.irct.ir\/trial\/935"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0191|cit191","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1089\/cap.2017.0055","article-title":"Simvastatin as an adjunctive therapy to risperidone in treatment of autism: a randomized, double-blind, placebo-controlled clinical trial","volume":"28","author":"Moazen-Zadeh","year":"2018","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0192|cit192","unstructured":"Amantadine in the treatment of autism www.irct.ir\/trial\/875"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0193|cit193","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/WNF.0b013e3182a9339d","article-title":"Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study","volume":"36","author":"Yadegari","year":"2013","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0194|cit194","unstructured":"Sulforaphane as adjunctive treatment of irritability in children with autism spectrum disorder www.irct.ir\/trial\/30363"},{"issue":"7","key":"10.1002\/14651858.CD011769.pub2-BIB0195|cit195","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/pcn.13016","article-title":"Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: a randomized, double-blind, placebo-controlled clinical trial","volume":"74","author":"Montazmenesh","year":"2020","journal-title":"Psychiatry and Clinical Neurosciences"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0196|cit196","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/1745-6215-15-230","article-title":"Fluoxetine for autistic behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism","volume":"15","author":"Mouti","year":"2014","journal-title":"Trials"},{"issue":"16","key":"10.1002\/14651858.CD011769.pub2-BIB0197|cit197","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1001\/jama.2019.14685","article-title":"Effect of fluoxetine on obsessive-compulsive behaviours in children and adolescents with autism spectrum disorders: a randomized clinical trial","volume":"322","author":"Reddihough","year":"2019","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0198|cit198","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3389\/fpsyt.2016.00002","article-title":"Oxytocin for male subjects with autism spectrum disorder and comorbid intellectual disabilities: a randomized pilot study","volume":"7","author":"Munesue","year":"2016","journal-title":"Frontiers in Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0199|cit199","unstructured":"A randomized, double-blind, placebo-controlled, cross-over trial of oxytocin in patients with autism spectrum disorder center6.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000008548"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0200|cit200","unstructured":"Early intervention with fluoxetine in autism clinicaltrials.gov\/ct2\/show\/NCT00183339"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0201|cit201","unstructured":"Evaluating the effectiveness of aripiprazole and D-cycloserine to treat symptoms associated with autism clinicaltrials.gov\/ct2\/show\/NCT00198107"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0202|cit202","unstructured":"Efficacy of aripiprazole versus placebo in the reduction of aggressive and aberrant behavior in autistic children (Abilify) clinicaltrials.gov\/ct2\/show\/NCT00468130"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0203|cit203","unstructured":"Effectiveness of atomoxetine in treating ADHD symptoms in children and adolescents with autism clinicaltrials.gov\/ct2\/show\/NCT00498173"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0204|cit204","unstructured":"Intranasal oxytocin for the treatment of autism spectrum disorders (INOT) clinicaltrials.gov\/ct2\/show\/NCT01337687"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0205|cit205","unstructured":"A study to evaluate the efficacy and safety of risperidone (R064766) in children and adolescents with irritability associated with autistic disorder clinicaltrials.gov\/ct2\/show\/NCT01624675"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0206|cit206","unstructured":"Intranasal oxytocin for the treatment of children and adolescents with autism spectrum disorders (ASD) (OXY-R) clinicaltrials.gov\/ct2\/show\/NCT01908205"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0207|cit207","unstructured":"Behavioral and neural response to memantine in adolescents with autism spectrum disorder clinicaltrials.gov\/ct2\/show\/NCT01972074"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0208|cit208","unstructured":"Neural and behavioral effects of oxytocin in autism spectrum disorders clinicaltrials.gov\/ct2\/show\/NCT02940574"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0209|cit209","unstructured":"Impact of combined medication and behavioral treatment for ASD & ADHD clinicaltrials.gov\/ct2\/NCT03242772?term=NCT03242772&draw=2&rank=1"},{"issue":"12","key":"10.1002\/14651858.CD011769.pub2-BIB0210|cit210","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1097\/00004583-200212000-00010","article-title":"Lofexidine In hyperactive and impulsive children with autistic disorder","volume":"41","author":"Niederhofer","year":"2002","journal-title":"Journal of the American Academy of Child & Adolescent Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0211|cit211","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/hup.491","article-title":"Tianeptine: a novel strategy of psychopharmacological treatment of children with autistic disorder","volume":"18","author":"Niederhofer","year":"2003","journal-title":"Human Psychopharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0212|cit212","unstructured":"N-acetylcysteine in the treatment of autism en.irct.ir\/trial\/879"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0213|cit213","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/WNF.0000000000000063","article-title":"N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety","volume":"38","author":"Nikoo","year":"2015","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0214|cit214","unstructured":"Comparing efficacy and side effects of memantine and risperidone in treating autistic patients www.irct.ir\/trial\/7627"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0215|cit215","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1055\/s-0042-108449","article-title":"Comparing efficacy and side effects of memantine vs risperidone in the treatment of autistic disorder","volume":"50","author":"Nikvarz","year":"2017","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0216|cit216","unstructured":"Study of aripiprazole in the treatment of serious behavioral problems in children and adolescents with autistic disorder (AD) www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-005111-40\/results"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0217|cit217","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1002\/ana.21853","article-title":"Efficacy and safety of flexibly-dosed aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years)","volume":"66","author":"Lewis","year":"2009","journal-title":"Annals of Neurology"},{"issue":"11 (Supp 3)","key":"10.1002\/14651858.CD011769.pub2-BIB0218|cit218","first-page":"A428","article-title":"Efficacy and safety of aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years): results from two 8-week randomized, double-blind, placebo-controlled trials","volume":"72","author":"Lewis","year":"2009","journal-title":"Neurology"},{"issue":"8","key":"10.1002\/14651858.CD011769.pub2-BIB0219|cit219","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1089\/cap.2012.0075","article-title":"Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change","volume":"23","author":"Mankoski","year":"2013","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0220|cit220","unstructured":"Study of aripiprazole in the treatment of serious behavioral problems in children and adolescents with autistic disorder (AD) clinicaltrials.gov\/ct2\/show\/NCT00365859"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0221|cit221","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1542\/peds.2008-3782","article-title":"Aripiprazole in the treatment of irritability in children and adolescent with autistic disorder","volume":"124","author":"Owen","year":"2009","journal-title":"Pediatrics"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0222|cit222","doi-asserted-by":"publisher","first-page":"PCC.10m01008","DOI":"10.4088\/PCC.10m01008gry","article-title":"Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years old): results from a pooled analysis of 2 studies","volume":"13","author":"Robb","year":"2011","journal-title":"Primary Care Companion for CNS Disorders"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0223|cit223","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.clinthera.2012.02.023","article-title":"The effect of aripiprazole 2 to 15mg\/day on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post-hoc analysis of two controlled trials","volume":"34","author":"Varni","year":"2012","journal-title":"Clinical Therapeutics"},{"issue":"11","key":"10.1002\/14651858.CD011769.pub2-BIB0224|cit224","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1097\/00004583-200111000-00009","article-title":"Multisite, double-blind, placebo-controlled trial of porcine secretin in autism","volume":"40","author":"Owley","year":"2001","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0225|cit225","unstructured":"Intranasal oxytocin treatment for social deficits in children with autism clinicaltrials.gov\/ct2\/show\/NCT01624194"},{"issue":"30","key":"10.1002\/14651858.CD011769.pub2-BIB0226|cit226","doi-asserted-by":"publisher","first-page":"8119-24","DOI":"10.1073\/pnas.1705521114","article-title":"Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism","volume":"114","author":"Parker","year":"2017","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0227|cit227","unstructured":"The role of vasopressin in the social deficits of autism clinicaltrials.gov\/ct2\/show\/NCT01962870"},{"issue":"491","key":"10.1002\/14651858.CD011769.pub2-BIB0228|cit228","doi-asserted-by":"publisher","first-page":"eaau7356","DOI":"10.1126\/scitranslmed.aau7356","article-title":"A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism","volume":"11","author":"Parker","year":"2019","journal-title":"Science Translational Medicine"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0229|cit229","unstructured":"Methylphenidate for attention deficit hyperactivity disorder and autism in children www.clinicaltrials.gov\/ct2\/show\/NCT00178503"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0230|cit230","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/cap.2012.0096","article-title":"Effects of extended release methylphenidate treatment on ratings of attention-deficit\/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms","volume":"23","author":"Pearson","year":"2013","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0231|cit231","unstructured":"Methylphenidate in children and adolescents with pervasive developmental disorders clinicaltrials.gov\/ct2\/show\/NCT00025779"},{"issue":"11","key":"10.1002\/14651858.CD011769.pub2-BIB0232|cit232","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/archpsyc.62.11.1266","article-title":"Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity","volume":"62","author":"Research Units on Pediatric Psychopharmacology (RUPP) Autism Network","year":"2005","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0233|cit233","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1089\/cap.2016.0107","article-title":"Using a patient-centered outcome measure to test methylphenidate versus placebo in children with autism spectrum disorder","volume":"27","author":"Scahill","year":"2017","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0234|cit234","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/BF02179289","article-title":"Use of methylphenidate in the treatment of children with autistic disorder","volume":"25","author":"Quintana","year":"1995","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0235|cit235","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/00004714-200108000-00012","article-title":"Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study","volume":"21","author":"Remington","year":"2001","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0236|cit236","unstructured":"Sloman L Remington G Konstantareas M Parker K Haloperidol versus clomipramine in autistic disorder 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 to June 4; Toronto (ON), Canada 1998"},{"issue":"7","key":"10.1002\/14651858.CD011769.pub2-BIB0237|cit237","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1176\/appi.ajp.162.7.1361","article-title":"Risperidone treatment for autistic disorder: longer-term benefits and blinded discontinuation after 6 months","volume":"162","author":"Research Units on Pediatric Psychopharmacology Autism Network","year":"2005","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0238|cit238","unstructured":"Topiramate in the treatment of autism www.irct.ir\/trial\/859"},{"issue":"7","key":"10.1002\/14651858.CD011769.pub2-BIB0239|cit239","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.pnpbp.2010.07.005","article-title":"Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder","volume":"34","author":"Rezaei","year":"2010","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0240|cit240","doi-asserted-by":"publisher","first-page":"S607","DOI":"10.1016\/S0924-977X(17)31154-9","article-title":"Guanfacine as an alternative for autism spectrum disorder with hyperactivity symptoms","volume":"27","author":"Munoz Martinez","year":"2017","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0241|cit241","unstructured":"Guanfacine for the treatment of hyperactivity in pervasive developmental disorder clinicaltrials.gov\/ct2\/show\/NCT01238575"},{"issue":"8","key":"10.1002\/14651858.CD011769.pub2-BIB0242|cit242","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1038\/s41386-018-0039-3","article-title":"A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures","volume":"43","author":"Politte","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1002\/14651858.CD011769.pub2-BIB0243|cit243","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1176\/appi.ajp.2015.15010055","article-title":"Extended-release guanfacine for hyperactivity in children with autism spectrum disorder","volume":"172","author":"Scahill","year":"2015","journal-title":"American Journal of Psychiatry"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011769.pub2-BIB0244|cit244","doi-asserted-by":"publisher","first-page":"S278","DOI":"10.1016\/S0924-977X(04)80324-9","article-title":"P2.104 Efficacy and safety of risperidone in the treatment of children with autistic and other pervasive developmental disorders (PDD): a randomized, double-blind, placebo controlled trial","volume":"14","author":"Light","year":"2004","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0245|cit245","doi-asserted-by":"publisher","first-page":"S275","DOI":"10.1016\/S0924-977X(04)80324-9","article-title":"Efficacy and safety of risperidone in the treatment of children with autistic and other pervasive developmental disorders (PDD): a randomized, double-blind, placebo controlled trial","volume":"7","author":"Light","year":"2004","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0246|cit246","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s10803-006-0234-7","article-title":"Risperidone improves behavioural symptoms in children with autism in a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Pandina","year":"2007","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0247|cit247","doi-asserted-by":"publisher","first-page":"e634","DOI":"10.1542\/peds.2003-0264-F","article-title":"Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders","volume":"114","author":"Shea","year":"2004","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0248|cit248","unstructured":"Study of oxytocin in autism to improve reciprocal social behaviours (SOARS-B) clinicaltrials.gov\/ct2\/show\/NCT01944046"},{"issue":"9","key":"10.1002\/14651858.CD011769.pub2-BIB0249|cit249","first-page":"145S","article-title":"Pilot study of sustained oxytocin treatment in children and adolescents with autistic disorder","volume":"73","author":"Sikich","year":"2013","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0250|cit250","unstructured":"Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors (SOARS-B) clinicaltrails.gov\/ct2\/show\/study\/NCT01944046?term=NCT01944046&draw=2&rank=1"},{"issue":"16","key":"10.1002\/14651858.CD011769.pub2-BIB0251|cit251","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1056\/NEJMoa2103583","article-title":"Intranasal oxytocin in children and adolescents with autism spectrum disorder","volume":"385","author":"Sikich","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD011769.pub2-BIB0252|cit252","doi-asserted-by":"publisher","first-page":"S162","DOI":"10.1016\/j.jaac.2021.09.087","article-title":"Randomized, placebo-controlled trial with open-label extension of intranasal oxytocin for autism spectrum disorder","volume":"60","author":"Spanos","year":"2021","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0253|cit253","unstructured":"A multi-site double-blind placebo-controlled trial of memantine versus placebo in children with autism (MEM) clinicaltrials.gov\/ct2\/show\/NCT01372449?term=NCT01372449&draw=1&rank=1"},{"issue":"7","key":"10.1002\/14651858.CD011769.pub2-BIB0254|cit254","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1089\/cap.2021.0010","article-title":"Neurocognitive outcomes from memantine: a pilot, double-blind, placebo-controlled trial in children with autism spectrum disorder","volume":"31","author":"Soorya","year":"2021","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0255|cit255","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.1016\/j.euroneuro.2020.09.108","article-title":"Bumetanide versus placebo for core symptoms of autism spectrum disorder at 91 days (BAMBI): a single-centre, double-blinded, patient-randomized, placebo-controlled, phase-2-trial","volume":"40","author":"Sprengers","year":"2020","journal-title":"European Neuropsychopharmacology"},{"issue":"7","key":"10.1002\/14651858.CD011769.pub2-BIB0256|cit256","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jaac.2020.07.888","article-title":"Bumetanide for core symptoms of autism spectrum disorder (BAMBI): a single center, double-blinded, participant-randomized, placebo-controlled, phase-2 superiority trial","volume":"60","author":"Sprengers","year":"2021","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0257|cit257","unstructured":"A study of RG7314 to investigate efficacy and safety in individuals with autism spectrum disorders (ASD) clinicaltrials.gov\/ct2\/show\/NCT01793441"},{"issue":"10","key":"10.1002\/14651858.CD011769.pub2-BIB0258|cit258","doi-asserted-by":"publisher","first-page":"S231","DOI":"10.1016\/j.jaac.2018.09.308","article-title":"Effects of balovaptan on health-related quality of life of adult men with ASD: results from a phase 2 randomized double-blind placebo controlled study (Vanilla)","volume":"57","author":"Squassante","year":"2018","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0259|cit259","unstructured":"A randomized, double-blind and cross-over trial to examine effects of continuous administration of intranasal oxytocin on social dysfunction in subjects with autism spectrum disorders center6.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000008388"},{"issue":"11","key":"10.1002\/14651858.CD011769.pub2-BIB0260|cit260","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1093\/brain\/awv249","article-title":"Clinical and neural effects of six-week administration of oxytocin on core symptoms of autism","volume":"138","author":"Watanabe","year":"2015","journal-title":"Brain"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0261|cit261","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/ebmh.9.2.56","article-title":"Discontinuing risperidone results in relapse in children with autism spectrum disorders","volume":"9","author":"Malone","year":"2006","journal-title":"Evidence-Based Mental Health"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0262|cit262","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1089\/cap.2006.16.561","article-title":"Neuropsychological effect of risperidone in children with pervasive developmental disorders: a blinded discontinuation study","volume":"16","author":"Troost","year":"2006","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD011769.pub2-BIB0263|cit263","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1097\/01.chi.0000177055.11229.76","article-title":"Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study","volume":"44","author":"Troost","year":"2005","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0264|cit264","unstructured":"A study of RO5028442 in adult male high-functioning autistic patients https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01474278?term=NCT01474278&draw=2&rank=1"},{"issue":"9","key":"10.1002\/14651858.CD011769.pub2-BIB0265|cit265","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1038\/npp.2016.232","article-title":"A single dose, randomized, controlled proof-of-mechanism study of a novel vasopressin 1a receptor antagonist (RG7713) in high-functioning adults with autism spectrum disorder","volume":"42","author":"Umbricht","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0266|cit266","unstructured":"Secretin for the treatment of autism clinicaltrials.gov\/ct2\/show\/NCT00065962"},{"issue":"11","key":"10.1002\/14651858.CD011769.pub2-BIB0267|cit267","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1097\/00004583-200211000-00012","article-title":"A randomized, double-blind, placebo-controlled trial of porcine versus synthetic secretin for reducing symptoms of autism","volume":"41","author":"Unis","year":"2002","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0268|cit268","doi-asserted-by":"publisher","first-page":"780281","DOI":"10.3389\/fpsyt.2022.780281","article-title":"Bumetanide for irritability in children with sensory processing problems across neurodevelopmental disorders: a pilot randomized controlled trial","volume":"13","author":"VanAndel","year":"2022","journal-title":"Frontiers in Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0269|cit269","unstructured":"Study of arbaclofen for the treatment of social withdrawal in subjects with autism spectrum disorders https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01288716?term=NCT01288716&draw=2&rank=1"},{"issue":"7","key":"10.1002\/14651858.CD011769.pub2-BIB0270|cit270","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/npp.2016.237","article-title":"Arbaclofen in children and adolescents with autism spectrum disorder: a randomized, controlled, phase 2 trial","volume":"42","author":"Veenstra-VanderWeele","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0271|cit271","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/01.yic.0000224787.13782.0f","article-title":"Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study","volume":"21","author":"Wasserman","year":"2006","journal-title":"International Clinical Psychopharmacology"},{"issue":"9","key":"10.1002\/14651858.CD011769.pub2-BIB0272|cit272","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1001\/archpsyc.1995.03950210060011","article-title":"Failure of naltrexone hydrochloride to reduce self-injurious and autistic behaviour in mentally retarded adults. Double-blind placebo-controlled studies","volume":"52","author":"Willemsen-Swinkels","year":"1995","journal-title":"Archives of General Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD011769.pub2-BIB0273|cit273","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/0006-3223(95)00297-9","article-title":"The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study","volume":"39","author":"Willemsen-Swinkels","year":"1996","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0274|cit274","unstructured":"A study of oral N-acetylcysteine in children with autism spectrum disorders https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00453180?term=NCT00453180&draw=2&rank=1"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0275|cit275","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13229-016-0088-6","article-title":"A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder","volume":"7","author":"Wink","year":"2016","journal-title":"Molecular Autism"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0276|cit276","unstructured":"Pilot study of riluzole for drug-refractory irritability in autism spectrum disorders https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02081027?term=NCT02081027&draw=2&rank=1"},{"issue":"9","key":"10.1002\/14651858.CD011769.pub2-BIB0277|cit277","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1007\/s10803-018-3562-5","article-title":"A randomized placebo-controlled cross-over pilot study of riluzole for drug-refractory irritability in autism spectrum disorder","volume":"48","author":"Wink","year":"2018","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0278|cit278","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/1362361307070989","article-title":"A placebo double-blind pilot study of dextromethorphan for problematic behaviors in children with autism","volume":"11","author":"Woodard","year":"2007","journal-title":"Autism"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0279|cit279","unstructured":"A multicenter, parallel group, placebo-controlled, double blind, confirmatory trial of intranasal oxytocin in participants with autism spectrum disorders https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-UMIN000015264"},{"issue":"8","key":"10.1002\/14651858.CD011769.pub2-BIB0280|cit280","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1038\/s41380-018-0097-2","article-title":"Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial","volume":"25","author":"Yamasue","year":"2020","journal-title":"Molecular Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0281|cit281","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.neuropsychologia.2015.10.025","article-title":"Oxytocin enhances orienting to social information in a selective group of high-functioning male adults with autism spectrum disorder","volume":"79","author":"Althaus","year":"2015","journal-title":"Neuropsychologia"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0282|cit282","first-page":"342","article-title":"Side effects associated with psychoactive medication in individuals with autism","volume":"27","author":"Aman","year":"1997","journal-title":"Journal of Autism & Developmental Disorders"},{"issue":"12","key":"10.1002\/14651858.CD011769.pub2-BIB0283|cit283","first-page":"1143","article-title":"Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial","volume":"48","author":"Aman","year":"2009","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD011769.pub2-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1176\/ajp.141.10.1195","article-title":"Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms","volume":"141","author":"Anderson","year":"1984","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02211843","article-title":"The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children","volume":"19","author":"Anderson","year":"1989","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1023\/A:1024933904144","article-title":"The effectiveness of naltrexone in treating task attending, aggression, self-injury and stereotypic mannerisms of six young males with autism or pervasive developmental disorders","volume":"9","author":"Anderson","year":"1997","journal-title":"Journal of Developmental and Physical Disabilities"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.biopsych.2006.02.032","article-title":"Effects of short- and long-term risperidone treatment on prolactin levels in children with autism","volume":"61","author":"Anderson","year":"2007","journal-title":"Biological Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0288|cit288","first-page":"174","article-title":"The effects of risperidone on behaviors seen in children with pervasive developmental disorder and mental retardation in an educational setting","volume":"13","author":"Arman","year":"2003","journal-title":"Bulletin of Clinical Psychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD011769.pub2-BIB0289|cit289","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.jaac.2012.08.028","article-title":"Research Units of Pediatric Psychopharmacology (RUPP) autism network randomized clinical trial of parent training and medication: one-year follow-up","volume":"51","author":"Arnold","year":"2012","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0290|cit290","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/00004583-198705000-00011","article-title":"Fenfluramine response in high and low functioning autistic children","volume":"26","author":"August","year":"1985","journal-title":"Journal of the American Academy of Child & Adolescent Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD011769.pub2-BIB0291|cit291","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1016\/j.ridd.2013.05.028","article-title":"Psychopharmacological treatment in children and adolescents with autism spectrum disorders in Germany","volume":"34","author":"Bachmann","year":"2013","journal-title":"Research in Developmental Disabilities"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3109\/17518423.2014.904949","article-title":"Effects associated with on- and off-label stimulant treatment of core autism and ADHD symptoms exhibited by children with autism spectrum disorder","volume":"19","author":"Barnard-Brak","year":"2016","journal-title":"Developmental neurorehabilitation"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0293|cit293","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/BF01486969","article-title":"Fenfluramine treatment of autism: relationship of treatment response to blood levels of fenfluramine and norfenfluramine","volume":"17","author":"Beeghly","year":"1987","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0294|cit294","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41386-019-0544-z","article-title":"A placebo-controlled double-blind trial of cannabinoids in children and adolescents with autism spectrum disorder","volume":"44","author":"Castellanos","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD011769.pub2-BIB0295|cit295","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1177\/08830738020170111501","article-title":"Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders","volume":"17","author":"Chez","year":"2002","journal-title":"Journal of Child Neurology"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0296|cit296","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1055\/s-0035-1557175","article-title":"Donepezil hydrochloride: a double-blind study in autistic children","volume":"1","author":"Chez","year":"2003","journal-title":"Journal of Pediatric Neurology"},{"issue":"7","key":"10.1002\/14651858.CD011769.pub2-BIB0297|cit297","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1089\/cap.2015.0045","article-title":"A pilot study on the combination of applied behavior analysis and bumetanide treatment for children with autism","volume":"25","author":"Du","year":"2015","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0298|cit298","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/BF02207332","article-title":"Brief report: effects of fenfluramine on communicative, stereotypic, and inappropriate behaviors of autistic-type mentally handicapped individuals","volume":"21","author":"Duker","year":"1991","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"12","key":"10.1002\/14651858.CD011769.pub2-BIB0299|cit299","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1017\/S0012162200001481","article-title":"Effect of secretin on children with autism: a randomized controlled trial","volume":"42","author":"Dunn-Geier","year":"2000","journal-title":"Developmental Medicine and Child Neurology"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0300|cit300","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/BF02212855","article-title":"Fenfluramine treatment of twenty children with autism","volume":"19","author":"Ekman","year":"1989","journal-title":"Journal of Autism & Developmental Disorders"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0301|cit301","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.rasd.2012.07.006","article-title":"L-carnitine supplementation improves the behavioral symptoms in autistic children","volume":"7","author":"Fahmy","year":"2013","journal-title":"Research in Autism Spectrum Disorders"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0302|cit302","doi-asserted-by":"publisher","first-page":"347","DOI":"10.5428\/pcar20180508","article-title":"Efficacy of vitamin D combined with \u03c9-3 fatty acid in treatment of children with autism spectrum disorder","volume":"18","author":"Fang","year":"2018","journal-title":"Pharmaceutical Care and Research"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0303|cit303","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1023\/A:1025861522935","article-title":"High-dose pyridoxine and magnesium administration in children with autistic disorder: an absence of salutary effects in a double-blind, placebo-controlled study","volume":"27","author":"Findling","year":"1997","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0304|cit304","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0891-4222(87)90004-7","article-title":"Effects of fenfluramine on the behavior of autistic individuals","volume":"8","author":"Groden","year":"1987","journal-title":"Research in Developmental Disabilities"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0305|cit305","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/JCP.0b013e318285680c","article-title":"Managing disruptive and compulsive behaviors in adult with autistic disorder with gabapentin","volume":"33","author":"Guglielmo","year":"2013","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0306|cit306","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10882-012-9316-y","article-title":"Use of a direct observational measure in a trial of risperidone and parent training in children with pervasive developmental disorders","volume":"25","author":"Handen","year":"2013","journal-title":"Journal of Developmental & Physical Disabilities"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0307|cit307","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1089\/10445460152595559","article-title":"Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism","volume":"11","author":"Hellings","year":"2001","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0308|cit308","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10803-006-0078-1","article-title":"A crossover study of risperidone in children, adolescents and adults with mental retardation","volume":"36","author":"Hellings","year":"2006","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0309|cit309","unstructured":"Napolitano D The effects of risperidone on the self-injury, aggression, and stereotypy of persons with developmental disabilities: observer agreement using direct observations and the aberrant behavior checklis during a double-blind placebo-controlled clinical Dissertation Abstracts International: Section B: The Sciences and Engineering 2001 61 8-B 4384"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0310|cit310","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1352\/0895-8017(2001)106<0525:EOROAB>2.0.CO;2","article-title":"Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double blind crossover study using multiple measures","volume":"106","author":"Zarcone","year":"2001","journal-title":"American Journal of Mental Retardation"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0311|cit311","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/19315864.2010.494763","article-title":"Long-term safety and adverse events of risperidone in children, adolescents, and adults with pervasive developmental disorders","volume":"3","author":"Hellings","year":"2010","journal-title":"Journal of Mental Health Research in Intellectual Disabilities"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0312|cit312","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1089\/cap.2014.0003","article-title":"Loxapine add-on for adolescents and adults with autism spectrum disorders and irritability","volume":"25","author":"Hellings","year":"2015","journal-title":"Journal of Child & Adolescent Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0313|cit313","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/19315861003690588","article-title":"A comparison of psychotropic drug side effect profiles in adults diagnosed with intellectual disabilities and autism spectrum disorders","volume":"3","author":"Hess","year":"2010","journal-title":"Journal of Mental Health Research in Intellectual Disabilities"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0314|cit314","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/sj.npp.1300021","article-title":"Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders","volume":"28","author":"Hollander","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0315|cit315","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1089\/cap.2006.16.541","article-title":"A double-blind placebo-controlled pilot study of olanzapine in childhood\/adolescent pervasive developmental disorder","volume":"16","author":"Hollander","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"10","key":"10.1002\/14651858.CD011769.pub2-BIB0316|cit316","doi-asserted-by":"publisher","first-page":"S262","DOI":"10.1016\/j.jaac.2020.08.458","article-title":"A phase 2 randomized controlled trial of balovaptan in pediatric participants with autism spectrum disorder","volume":"59","author":"Hollander","year":"2020","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0317|cit317","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.rasd.2011.05.013","article-title":"The relationship between symptoms of autism spectrum disorders and psychotropic medication use in infants and toddlers","volume":"6","author":"Horovitz","year":"2013","journal-title":"Research in Autism Spectrum Disorders"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0318|cit318","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1023\/A:1025854532079","article-title":"Risperidone and explosive aggressive autism","volume":"27","author":"Horrigan","year":"1997","journal-title":"Journal of Autism & Developmental Disorders"},{"issue":"95","key":"10.1002\/14651858.CD011769.pub2-BIB0319|cit319","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1179\/096979502799104229","article-title":"Risperidone in children and adolescents with autistic disorder and aggressive behaviour","volume":"48","author":"Hughes","year":"2002","journal-title":"British Journal of Developmental Disabilities"},{"issue":"10","key":"10.1002\/14651858.CD011769.pub2-BIB0320|cit320","doi-asserted-by":"publisher","first-page":"S163","DOI":"10.1016\/j.jaac.2020.08.108","article-title":"Phase 3 randomized controlled trial of balovaptan in adults with autism spectrum disorder","volume":"59","author":"Jacob","year":"2020","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0321|cit321","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00213-012-2723-z","article-title":"Aripiprazole in the treatment of challenging behaviour in adults with autism spectrum disorder","volume":"223","author":"Jordan","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0322|cit322","unstructured":"A randomized, double-blind, placebo-controlled, cross-over trial of oxytocin in patients with autism spectrum disorder http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-UMIN000007250 2012 http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-UMIN000007250"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0323|cit323","first-page":"173","article-title":"Double blind crossover study of secretin\/secrepan treatment for children with autistic symptoms","volume":"12","year":"2000","journal-title":"Tzu Chi Medical Journal"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0324|cit324","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/00004583-199502000-00018","article-title":"Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study","volume":"34","author":"Kolmen","year":"1995","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD011769.pub2-BIB0325|cit325","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/S0890-8567(09)66567-9","article-title":"Naltrexone in young autistic children: replication study and learning measures","volume":"36","author":"Kolmen","year":"1997","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"2-B","key":"10.1002\/14651858.CD011769.pub2-BIB0326|cit326","first-page":"1032","article-title":"Effects of repeated secretin administration on a subset of children with pervasive developmental disorder","volume":"65","author":"Krusch","year":"2004","journal-title":"Dissertation Abstracts International: Section B: The Sciences and Engineering"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0327|cit327","first-page":"95","article-title":"Opioid hypothesis in infantile autism? Therapeutic trials with naltrexone","volume":"19","author":"Leboyer","year":"1993","journal-title":"Encephale"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0328|cit328","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1038\/tp.2012.124","article-title":"A randomised controlled trial of bumetanide in the treatment of autism in children","volume":"2","author":"Lemonnier","year":"2012","journal-title":"Translational Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0329|cit329","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1176\/jnp.5.3.307","article-title":"Clinical and neurochemical effects of fenfluramine in children with autism","volume":"5","author":"Leventhal","year":"1993","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences"},{"issue":"2-3","key":"10.1002\/14651858.CD011769.pub2-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF01273191","article-title":"Inositol treatment of autism","volume":"104","author":"Levine","year":"1997","journal-title":"Journal of Neural Transmission"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/00004583-200202000-00007","article-title":"Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness","volume":"41","author":"Malone","year":"2002","journal-title":"Journal of the American Academy of Child & Adolescent Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0332|cit332","unstructured":"A comparative study on the effectiveness of risperidone versus risperidone plus naltrexone in treatment of autistic spectrum disorder in children with 6-12 years old www.irct.ir\/trial\/5631"},{"issue":"12","key":"10.1002\/14651858.CD011769.pub2-BIB0333|cit333","doi-asserted-by":"publisher","first-page":"6375","DOI":"10.22038\/ijp.2017.18557.1516","article-title":"Comparative study on the effect of risperidone and its combination with naltrexone in pediatric patients with autistic spectrum disorders: a clinical trial study","volume":"5","author":"Moharreri","year":"2017","journal-title":"International Journal of Pediatrics"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0334|cit334","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/08830738060210060801","article-title":"Risperidone in children with autism: randomized, placebo-controlled, double-blind study","volume":"21","author":"Nagaraj","year":"2006","journal-title":"Journal of Child Neurology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0335|cit335","unstructured":"Safety and effectiveness of D-Cycloserine in children with autism https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00198120?term=NCT00198120&draw=2&rank=1"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0336|cit336","unstructured":"Memantine in adult autism spectrum disorder https:\/\/clinicaltrials.gov\/study\/NCT01078844 (not published - terminated)"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0337|cit337","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/DBP.0b013e31815f24f7","article-title":"Stimulant medication treatment of target behaviors in children with autism: a population-based study","volume":"29","author":"Nickels","year":"2008","journal-title":"Journal of Developmental & Behavioral Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0338|cit338","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/01.jcp.0000270082.30500.69","article-title":"Glutamate antagonists seem to be slightly effective in psychopharmacologic treatment of autism","volume":"27","author":"Niederhofer","year":"2007","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD011769.pub2-BIB0339|cit339","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1176\/appi.ajp.161.11.2115","article-title":"A pilot study of D-cycloserine in subjects with autistic disorder","volume":"161","author":"Posey","year":"2004","journal-title":"The American journal of psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0340|cit340","unstructured":"Oxytocin-induced enhancement of Social Skills Training in Adolescents with ASD http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=DRKS00008952 2015 2015"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0341|cit341","doi-asserted-by":"crossref","unstructured":"Mayer A Preckel K Ihle K Piecha F Junghanns K Reiche S No support for oxytocin modulation of reward-related brain function in autism: evidence from a randomized controlled trial https:\/\/www.medrxiv.org\/content\/10.1101\/2021.03.19.21253900v1 2021 10.1101\/2021.03.19.21253900","DOI":"10.1101\/2021.03.19.21253900"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0342|cit342","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12888-016-1036-x","article-title":"Clinical trial of modulatory effects of oxytocin treatment on higher-order social cognition in autism spectrum disorder: a randomized, placebo-controlled, double-blind and crossover trial","volume":"16","author":"Preckel","year":"2016","journal-title":"BMC Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD011769.pub2-BIB0343|cit343","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/070674379403900703","article-title":"Risperidone in the Treatment of Pervasive Developmental Disorder","volume":"39","author":"Purdon","year":"1994","journal-title":"Canadian Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0344|cit344","first-page":"21","article-title":"An effect of long-term cerebrolysin therapy in combination with neuroleptics on behavioral and cognitive disturbances in endogenous childhood autism","volume":"106","author":"Radzivil","year":"2006","journal-title":"Zhurnal Nevrologii i Psikhiatrii Imen"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0345|cit345","first-page":"256","article-title":"Randomized controlled trial of transdermal secretin on behavior of children with autism","volume":"9","author":"Ratcliff-Schaub","year":"2005","journal-title":"the international journal of research and practice"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0346|cit346","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/BF01537957","article-title":"Effects of L-dopa in autism","volume":"1","author":"Ritvo","year":"1971","journal-title":"Journal of Autism & Childhood Schizophrenia"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0347|cit347","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/00004583-198311000-00006","article-title":"Effects of fenfluramine on 14 outpatients with the syndrome of autism","volume":"22","author":"Ritvo","year":"1983","journal-title":"Journal of the American Academy of Child Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0348|cit348","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0022-3476(84)80316-9","article-title":"Study of fenfluramine in outpatients with the syndrome of autism","volume":"105","author":"Ritvo","year":"1984","journal-title":"The Journal of pediatrics"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0349|cit349","doi-asserted-by":"publisher","first-page":"E71","DOI":"10.1542\/peds.107.5.e71","article-title":"Repeated doses of porcine secretin in the treatment of autism: a randomized, placebo-controlled trial","volume":"107","author":"Roberts","year":"2001","journal-title":"Pediatrics"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0350|cit350","first-page":"301","article-title":"A double-blind trial with naltrexone in autism","volume":"4","author":"Scifo","year":"1991","journal-title":"Brain Dysfunction"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0351|cit351","first-page":"351","article-title":"Opioid-immune interactions in autism: behavioural and immunological assessment during a double-blind treatment with naltrexone","volume":"32","author":"Scifo","year":"1996","journal-title":"Annali dell'Istituto superiore di sanit\u00e0"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0352|cit352","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1651-2227.2002.tb03274.x","article-title":"Multiple doses of secretin in the treatment of autism: a controlled study","volume":"91","author":"Sponheim","year":"2002","journal-title":"Acta paediatrica"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0353|cit353","first-page":"15","article-title":"Fluoxetine's efficacy in improving physical symptoms associated with pdd: results from a multisite, randomized, placebo-controlled trial","author":"Steiner","year":"1999","journal-title":"Proceedings of the 152nd annual meeting of the American Psychiatric Association"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0354|cit354","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1469-8749.1986.tb03859.x","article-title":"Effects of fenfluramine on eight outpatients with the syndrome of autism","volume":"28","author":"Stubbs","year":"1986","journal-title":"Developmental medicine and child neurology"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0355|cit355","first-page":"233","article-title":"Studies on the adverse effects of fluvoxamine treatment in children with autistic disorder: correlation with genetic polymorphism in serotonin related genes","volume":"35","author":"Sugie","year":"2003","journal-title":"No to Hattatsu [Brain & Development]"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0356|cit356","first-page":"51","article-title":"Low-dose levodopa therapy of autistic disorder: evaluation of clinical effectiveness","volume":"30","author":"Sugiyama","year":"1998","journal-title":"No to Hattatsu [Brain and Development]"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0357|cit357","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1089\/cap.2012.0048","article-title":"Long-term administration of intranasal oxytocin is a safe and promising therapy for early adolescent boys with autism spectrum disorders","volume":"23","author":"Tachibana","year":"2013","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0358|cit358","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/BF01046596","article-title":"Naltrexone improves learning and attention in self-injurious individuals with developmental disabilities","volume":"5","author":"Taylor","year":"1993","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0359|cit359","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/BF01066428","article-title":"Fluoxetine in autism","volume":"23","author":"Tolbert","year":"1993","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0360|cit360","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1089\/cap.2006.16.611","article-title":"Atomoxetine for attention-deficit\/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study","volume":"16","author":"Troost","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0361|cit361","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1056\/NEJM198307213090317","article-title":"Irritability in autistic children treated with fenfluramine","volume":"309","author":"Volkmar","year":"1983","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0362|cit362","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1001\/archgenpsychiatry.2009.42","article-title":"Citalopram treatment in children with autism spectrum disorders and high levels of repetitive behavior","volume":"66","author":"Volkmar","year":"2009","journal-title":"Archives of General Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD011769.pub2-BIB0363|cit363","doi-asserted-by":"publisher","first-page":"166S","DOI":"10.1017\/S1461145705005791","article-title":"Divalproex sodium vs. placebo in the treatment of repetitive behaviors and the treatment of activation associated with fluoxetine in autism spectrum disorder","volume":"57","author":"Wasserman","year":"2005","journal-title":"Biological Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0364|cit364","first-page":"216","article-title":"Treatment of behavioral disorders by risperidone in children with autism","volume":"13","author":"Wei","year":"2011","journal-title":"Zhongguo Dangdai Erke Zazhi"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0365|cit365","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1089\/cap.2005.15.671","article-title":"Treatment incidence and patterns in children and adolescents with autism spectrum disorders","volume":"15","author":"Witwer","year":"2005","journal-title":"Journal of Child & Adolescent Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0366|cit366","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/BF01487062","article-title":"Effects of fenfluramine on autistic individuals residing in a state developmental centre","volume":"17","author":"Yarbrough","year":"1987","journal-title":"Journal of autism and developmental disorders"},{"issue":"8","key":"10.1002\/14651858.CD011769.pub2-BIB0367|cit367","first-page":"934","article-title":"Useful pharmacologic treatment in impaired social interaction in autism spectrum disorders","volume":"114","author":"Yui","year":"2012","journal-title":"Seishin Shinkeigaku Zasshi - Psychiatria et Neurologia Japonica"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0368|cit368","first-page":"57","article-title":"Clinical effects of naltrexone on autistic behavior","volume":"97","author":"Zingarelli","year":"1992","journal-title":"American Journal on Mental Retardation"},{"issue":"10","key":"10.1002\/14651858.CD011769.pub2-BIB0369|cit369","doi-asserted-by":"publisher","first-page":"S232","DOI":"10.1016\/j.jaac.2018.09.311","article-title":"A phase 2 randomized, placebo-controlled trial of tideglusib, an orally administered GSK-3 beta inhibitor, in the treatment of adolescents with ASD","volume":"57","author":"Anagnostou","year":"2018","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0370|cit370","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/0924-977x(95)00049-u","article-title":"A controlled trial with ORG 2766, an ACTH-(4-9) analog, in 50 relatively able children with autism","volume":"6","author":"Buitelaar","year":"1996","journal-title":"European Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0371|cit371","first-page":"110","article-title":"Haloperidol in autistic children: effects on learning, behavior, and abnormal involuntary movements","volume":"18","author":"Campbell","year":"1982","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0372|cit372","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.pnpbp.2015.09.002","article-title":"Using venlafaxine to treat behavioral disorders in patients with autism spectrum disorder","volume":"65","author":"Carminati","year":"2016","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0373|cit373","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s12031-019-01351-7","article-title":"Improvement of language in children with autism with combined donepezil and choline treatment","volume":"69","author":"Gabis","year":"2019","journal-title":"Journal of Molecular Neuroscience"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0374|cit374","unstructured":"Treatment with acetyl-choline esterase inhibitors in children with autism spectrum disorders clinicaltrials.gov\/ct2\/show\/NCT01098383"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0375|cit375","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1023\/A:1005548619694","article-title":"Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder","volume":"30","author":"Handen","year":"2000","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0376|cit376","unstructured":"The efficacy of augmentation donepezil to risperidon in treatment of autism spectrum disorders www.irct.ir\/trial\/25769"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0377|cit377","unstructured":"Efficacy of N-acetyl cysteine in patients with autism spectrum disorder www.irct.ir\/trial\/41209"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0378|cit378","unstructured":"The efficacy and safety of pyridoxamine in patients with autism spectrum disorder; exploratory physician-led Phase 2 trial ww.trialsearch.who.int\/Trial2.aspx?trialID=JPRN-JMA-IIA00438"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0379|cit379","first-page":"111","article-title":"A double blind study of dimethylglycine treatment in children with autism","volume":"12","author":"Jung","year":"2000","journal-title":"A double blind study of dimethylglycine treatment in children with autism"},{"issue":"12","key":"10.1002\/14651858.CD011769.pub2-BIB0380|cit380","first-page":"1676","article-title":"Secretin treatment of autism?","volume":"164","author":"J\u00f8rgensen","year":"2002","journal-title":"Ugeskrift for Laeger"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0381|cit381","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2310\/7010.2001.17515","article-title":"Effectiveness of N,N-Dimethylglycine in autism and pervasive developmental disorder","volume":"16","author":"Kern","year":"2000","journal-title":"Journal of Child Neurology"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0382|cit382","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1023\/A:1015441428154","article-title":"Efficacy of porcine secretin in children with autism and pervasive developmental disorder","volume":"32","author":"Kern","year":"2002","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"16","key":"10.1002\/14651858.CD011769.pub2-BIB0383|cit383","first-page":"1893","article-title":"Efficacy and safety of paliperidone and aripiprazole in the treatment of autism","volume":"25","author":"Ma","year":"2016","journal-title":"Chinese Journal of New Drugs"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0384|cit384","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1089\/cap.2010.2064","article-title":"Metabolic effects of olanzapine in children with autistic disorder","volume":"20","author":"Malone","year":"2010","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0385|cit385","unstructured":"A controlled sudy of olanzapine in children with autism clinicaltrials.gov\/ct2\/show\/NCT00057408"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0386|cit386","doi-asserted-by":"publisher","first-page":"S729","DOI":"10.1016\/S0924-977X(16)31879-X","article-title":"The safety and efficacy of memantine hydrochloride versus placebo for children under 3 years old with autism spectrum disorders","volume":"26","author":"Martsenkovsky","year":"2016","journal-title":"European Neuropsychopharmacology"},{"issue":"19","key":"10.1002\/14651858.CD011769.pub2-BIB0387|cit387","first-page":"667","article-title":"Mode of action of sulpiride in autistic children. A double blind study","volume":"121","author":"Miller","year":"1979","journal-title":"M\u00fcnchener Medizinische Wochenschrift"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0388|cit388","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1023\/A:1021202930206","article-title":"Lack of benefit of intravenous synthetic human secretin in the treatment of autism","volume":"32","author":"Molloy","year":"2002","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0389|cit389","first-page":"629","article-title":"A multi centered double blind trial of pimozide (Orap), haloperidol and placebo for abnormal behavior in children using crossover design","volume":"8","author":"Hyoka","year":"1980","journal-title":"Clinical Evaluation"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0390|cit390","first-page":"173","article-title":"A multi-center double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavioral disorders, using crossover design","volume":"48","author":"Naruse","year":"1982","journal-title":"Acta Paedopsychiatrica"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0391|cit391","doi-asserted-by":"publisher","first-page":"S291","DOI":"10.1038\/npp.2014.281","article-title":"Milnacipran vs placebo in adult autism spectrum disorder: impact on hyperactivity","volume":"39","author":"Noone","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0392|cit392","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1017\/S146114570400433X","article-title":"Increased repetitive behaviours and prolactin responsivity to oral m-chlorophenylpiperazine in adults with autism spectrum disorders","volume":"7","author":"Novotny","year":"2004","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"24","key":"10.1002\/14651858.CD011769.pub2-BIB0393|cit393","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1056\/NEJM199912093412404","article-title":"Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder","volume":"341","author":"Sandler","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0394|cit394","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/j.1469-7610.1990.tb00798.x","article-title":"A controlled crossover trial of fenfluramine in autism","volume":"31","author":"Stern","year":"1990","journal-title":"Journal of Child Psychology and Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0395|cit395","unstructured":"Study of intranasal ketamine for social impairment in autism spectrum disorder Search of: NCT02611921 - List Results - ClinicalTrials.gov"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0396|cit396","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1007\/s10803-020-04542-z","article-title":"Brief Report: intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder\u2014Initial Results of a Randomized, Controlled, Crossover, Pilot Study","volume":"51","author":"Wink","year":"2020","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"9","key":"10.1002\/14651858.CD011769.pub2-BIB0397|cit397","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/mp.2015.162","article-title":"The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial","volume":"21","author":"Yatawara","journal-title":"Molecular Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0398|cit398","unstructured":"The feasibility of magnetic resonance imaging in a non-selective comprehensive clinical trial in pediatric autism spectrum disorder australianclinicaltrials.gov.au\/anzctr\/trial\/ACTRN12617000441314"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0399|cit399","unstructured":"A random, double-blind, placebo controlled trial for oxytocin nasal spray in the treatment for ASD social dysfunction www.chictr.org.cn\/showprojen.aspx?proj=29953"},{"issue":"8","key":"10.1002\/14651858.CD011769.pub2-BIB0400|cit400","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1007\/s10803-020-04709-8","article-title":"Bumetanide oral liquid formulation for the treatment of children and adolescents with autism spectrum disorder: design of two phase III studies (SIGN Trials)","volume":"51","author":"Crutel","year":"2020","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0401|cit401","unstructured":"Comparison of the efficacy of oral risperidone and aripiprazole in children with autism spectrum disorders (ASDs) aged 6-18 years: a double blind randomized controlled trial - RAAT www.trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2021\/12\/038721"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0402|cit402","unstructured":"Study of the clinical and neurofunctional response to fluoxetine in childhood autism (FAIR) www.clinicaltrialsregister.eu\/ctr-search\/trial\/2008-003712-36\/FR"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0403|cit403","unstructured":"Group-therapy, autism and oxytocin - an investigation with the question \"Does oxytocin (OT) enhance therapy effects in autism?\" www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-024202-34\/DE"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0404|cit404","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13063-016-1266-8","article-title":"Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) \u2013 study protocol for a randomised controlled trial","volume":"17","author":"H\u00e4ge","year":"2016","journal-title":"Trials"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0405|cit405","unstructured":"Cilostazol in the treatment of autism www.irct.ir\/trial\/48108"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0406|cit406","unstructured":"The effect of ondansetron on autism www.irct.ir\/trial\/46589"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0407|cit407","unstructured":"Sertraline for anxiety in adults with a diagnosis of autism (STRATA) a randomised controlled trial Australianclinicaltrials.gov.au\/anzctr\/trial\/ACTRN12621000801819"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0408|cit408","unstructured":"Sertraline for anxiety in adults with a diagnosis of autism www.isrtcn.com\/ISRTCN15984604"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0409|cit409","unstructured":"Effects of long-term administration of intranasal oxytocin in children with autism spectrum disorder https:\/\/center6.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000020712"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0410|cit410","unstructured":"Safety and effectiveness of D-cycloserine in children with autism clinicaltrials.gov\/ct2\/show\/NCT00198120"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0411|cit411","unstructured":"A randomized, controlled trial of intranasal oxytocin as an adjunct to behavioral therapy for autism spectrum disorder clinicaltrials.gov\/ct2\/show\/NCT01914939"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0412|cit412","unstructured":"A pilot treatment study of insulin-like growth factor-1 (IGF-1) in autism spectrum disorder clinicaltrials.gov\/ct2\/show\/NCT01970345"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0413|cit413","unstructured":"Memantine for the treatment of social deficits in youth with disorders of impaired social interactions clinicaltrials.gov\/show\/NCT03553875"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0414|cit414","unstructured":"Arbaclofen vs. Placebo in the Treatment of Children and Adolescents With ASD clinicaltrials.gov\/ct2\/show\/NCT03887676?term=NCT03887676%draw=2&rank=1"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0415|cit415","unstructured":"CASCADE: CAnnabidiol Study in Children with Autism Spectrum DisordEr clinicaltrials.gov\/ct2\/show\/NCT04520685"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0416|cit416","unstructured":"Amitriptyline for repetitive behaviors in autism spectrum disorders www.clinicaltrails.gov\/ct2\/showNCT04725383?term=NCT04725383&draw=2&rank=1"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0417|cit417","unstructured":"An exploratory, Phase 2, randomized, double-blind, placebo-controlled trial to investigate the safety and efficacy of cannabidiol oral solution (GWP42003-P; CBD-OS) in children and adolescents with autism spectrum disorder clinicaltrialregister.eu\/ctr-search\/trial\/2020-002819-21\/DE"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0418|cit418","unstructured":"Trial to investigate the safety and efficacy of cannabidiol oral solution (GWP42003-P; CBD-OS) in children and adolescents with autism spectrum disorder clinicaltrials.gov\/ct2\/show\/NCT04745026?term=NCT04745026&draw=2&rank=1"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0419|cit419","unstructured":"AB-2004 in Treatment of adolescents with irritability associated with autism spectrum sisorder (ASD) AB-2004 in Treatment of adolescents with irritability associated with autism spectrum disorder (ASD) - full text view - ClinicalTrials.gov"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0420|cit420","unstructured":"Cannabidiol (CBD) in adults With ASD Cannabidiol (CBD) in adults With ASD - full text view - ClinicalTrials.gov"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0421|cit421","unstructured":"INP105 proof-of-concept study for the acute treatment of agitation in adolescents with ASD (CALM 201) www.clinicaltrials.gov\/ct2\/show\/NCT05163717"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0422|cit422","unstructured":"SCI-210 in the treatment of children and young adults with autism evaluate the safety, tolerability and efficacy of SCI-210 in children with autism spectrum disorder (ASD) www.clinicaltrials.govct\/show\/NCT05182697?term=NCT05182697&draw=2&rank=1"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0423|cit423","unstructured":"Arbaclofen in children and adolescents with ASD (AIMS2-CT1) clinicaltrials.gov\/ct2\/show\/NCT03682978?term=NCT03682978&draw=2&rank=1"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0424|cit424","doi-asserted-by":"publisher","first-page":"701729","DOI":"10.3389\/fpsyt.2021.701729","article-title":"A phase II randomised, double-blind, placebo-controlled study of the efficacy, safety and tolerability of arbaclofen administered for the treatment of social function in children and adolescents with autism spectrum disorders - study protocol for AIMS-2-TRIALS-CT1","volume":"12","author":"Parellada","year":"2021","journal-title":"Frontiers in Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0425|cit425","unstructured":"Effects of long-term administration of intranasal oxytocin in children with autism spectrum disorder upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000020712"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0426|cit426","volume-title":"Manual for the ASEBA preschool forms and profiles","author":"Achenbach","year":"2000"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0427|cit427","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s40272-019-00333-x","article-title":"Safety and tolerability of antipsychotic medication in individuals with autism spectrum disorder: a systematic review and meta-analysis","volume":"21","author":"Alfageh","year":"2019","journal-title":"Pediatric Drugs"},{"issue":"7","key":"10.1002\/14651858.CD011769.pub2-BIB0428|cit428","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2165\/00023210-200822070-00002","article-title":"Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal","volume":"22","author":"Alvarez-Jim\u00e9nez","year":"2008","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0429|cit429","first-page":"485","article-title":"The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects","volume":"89","author":"Aman","year":"1985","journal-title":"American Journal of Mental Deficiency"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0430|cit430","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/0891-4222(95)00039-9","article-title":"The Nisonger CBRG: a child behavior rating form for children with developmental disabilities","volume":"17","author":"Aman","year":"1996","journal-title":"Research in Developmental Disabilities"},{"issue":"9","key":"10.1002\/14651858.CD011769.pub2-BIB0431|cit431","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.1073\/pnas.0910249107","article-title":"Promoting social behaviour with oxytocin in high-functioning autism spectrum disorders","volume":"107","author":"Andari","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0432|cit432","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/j.1469-7610.1987.tb00677.x","article-title":"Whole blood serotonin in autistic and normal subjects","volume":"28","author":"Anderson","year":"1987","journal-title":"Journal of Child Psychology and Psychiatry and allied disciplines"},{"issue":"10","key":"10.1002\/14651858.CD011769.pub2-BIB0433|cit433","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1586\/14737175.2013.840417","article-title":"The comorbidity of ADHD and autism spectrum disorder","volume":"13","author":"Antshel","year":"2013","journal-title":"Expert Review of Neurotherapeutics"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0434|cit434","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/B978-0-444-53717-1.00423-6","volume-title":"Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions","author":"Aronson","year":"2016"},{"issue":"7","key":"10.1002\/14651858.CD011769.pub2-BIB0435|cit435","doi-asserted-by":"publisher","first-page":"e1002615","DOI":"10.1371\/journal.pmed.1002615","article-title":"Neurodevelopmental disorders in children aged 2-9 years: population-based burden estimates across five regions in India","volume":"15","author":"Arora","year":"2018","journal-title":"PloS Medicine"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0436|cit436","unstructured":"How do we describe autism? https:\/\/www.autismspectrum.org.au\/blog\/how-do-we-describe-autism"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0437|cit437","unstructured":"Identity-first language https:\/\/autisticadvocacy.org\/about-asan\/identity-first-language\/"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0438|cit438","doi-asserted-by":"publisher","first-page":"e94112","DOI":"10.1371\/journal.pone.0094112","article-title":"Almost all antipsychotics result in weight gain: a meta-analysis","volume":"9","author":"Bak","year":"2014","journal-title":"PloS One"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0439|cit439","first-page":"110","article-title":"Clonidine as a treatment of behavioural disturbances in autism spectrum disorder: a systematic literature review","volume":"29","author":"Banas","year":"2020","journal-title":"Journal of the Canadian Academy of Child and Adolescent Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0440|cit440","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2217\/fnl.10.80","article-title":"Insights into synaptic function from mouse models of human cognitive disorders","volume":"6","author":"Banko","year":"2011","journal-title":"Future Neurology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0441|cit441","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198504900.001.0001","volume-title":"Autism and Asperger Syndrome","author":"Baron-Cohen","year":"2008"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0442|cit442","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00787-018-1234-9","article-title":"Suicidal behaviors and irritability in children and adolescents:a systematic review of the nature and mechanisms of the association","volume":"28","author":"Benarous","journal-title":"European Child and Adolescent Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0443|cit443","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s10882-016-9502-4","article-title":"Which aspects of challenging behaviour are associated with anxiety across two age groups of young males with an autism spectrum disorder?","volume":"28","author":"Bitsika","year":"2016","journal-title":"Journal of Developmental and Physical Disabilities"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0444|cit444","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1023\/A:1005596502855","article-title":"Varieties of repetitive behavior in autism: comparisons to mental retardation","volume":"30","author":"Bodfish","year":"2000","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0445|cit445","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1108\/AMHID-02-2018-0004","article-title":"Stopping over-medication of people with intellectual disability, autism or both (STOMP) in England part 1 \u2013 history and background of STOMP","volume":"13","author":"Branford","year":"2019","journal-title":"Advances in Mental Health and Intellectual Disabilities"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0446|cit446","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s10803-015-2619-y","article-title":"Pharmacological modulation of GABA function in autism spectrum disorders: a systematic review of human studies","volume":"46","author":"Brondino","year":"2016","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0447|cit447","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/aur.2419","article-title":"Identifying children and youth with autism spectrum disorder in electronic medical records: examining health system utilisation and comorbidities","volume":"14","author":"Brooks","year":"2021","journal-title":"Autism Research"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0448|cit448","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0165-1781(79)90053-2","article-title":"Aggression in humans correlates with cerebrospinal fluid amine metabolites","volume":"1","author":"Brown","year":"1979","journal-title":"Psychiatry Research"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0449|cit449","doi-asserted-by":"publisher","first-page":"390\u2013408","DOI":"10.1038\/s41380-018-0116-3","article-title":"Treatment strategies for ADHD: an evidence-based guide to select optimal treatment","volume":"24","author":"Caye","year":"2019","journal-title":"Molecular Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0450|cit450","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1089\/cap.2018.0021","article-title":"A retrospective chart review of buspirone for the treatment of anxiety in psychiatrically referred youth with high-functioning autism spectrum disorder","volume":"29","author":"Ceranoglu","year":"2019","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0451|cit451","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12868-017-0373-0","article-title":"Hippocampus and amygdala radiomic biomarkers for the study of autism spectrum disorder","volume":"18","author":"Chaddad","year":"2017","journal-title":"BMC Neuroscience"},{"issue":"10","key":"10.1002\/14651858.CD011769.pub2-BIB0452|cit452","doi-asserted-by":"publisher","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0453|cit453","doi-asserted-by":"publisher","first-page":"22996","DOI":"10.1038\/s41598-021-02040-5","article-title":"Effect of N\u2011Methyl\u2011D\u2011Aspartate receptor enhancing agents on cognition in dementia: an exploratory systematic review and meta\u2011analysis of randomized controlled trials","volume":"11","year":"2021","journal-title":"Scientific Reports"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0454|cit454","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1055\/s-0035-1557175","article-title":"Donepezil hydrochloride: a double-blind study in autistic children","volume":"1","author":"Chez","year":"2003","journal-title":"Journal of Pediatric Neurology"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD011769.pub2-BIB0455|cit455","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.1002\/ana.20263","article-title":"Memantine experience in children and adolescents with autistic spectrum disorders","volume":"56","author":"Chez","year":"2004","journal-title":"Annals of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0456|cit456","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009043.pub2","article-title":"Aripiprazole for autism spectrum disorders (ASD)","author":"Ching","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0457|cit457","doi-asserted-by":"publisher","first-page":"10","DOI":"10.4172\/2472-1786.100073","article-title":"Why do we find it so hard to calculate the burden of neurodevelopmental disorders?","volume":"4","author":"Cleaton","year":"2018","journal-title":"Journal of Childhood and Developmental Disorders"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0458|cit458","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0459|cit459","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.4103\/0028-3886.193801","article-title":"Levetiracetam as an antiepileptic, neuroprotective, and hyperalgesic drug","volume":"64","author":"Cortes-Altamirano","year":"2016","journal-title":"Neurology India"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0460|cit460","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1586\/ern.12.23","article-title":"Psychostimulants for ADHD-like symptoms in individuals with autism spectrum disorders","volume":"12","author":"Cortese","year":"2012","journal-title":"Expert Review of Neurotherapeutics"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011769.pub2-BIB0461|cit461","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1542\/peds.2012-0900D","article-title":"Use of psychotropic medication in children and adolescents with autism spectrum disorders","volume":"130","author":"Coury","year":"2012","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0462|cit462","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/aur.1449","article-title":"Overlap between autism spectrum disorders and attention deficit hyperactivity disorder: searching for distinctive\/common clinical features","volume":"3","author":"Craig","journal-title":"2015"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0463|cit463","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40501-017-0102-4","article-title":"Pharmacological management of anxiety disorders in the elderly","volume":"4","author":"Crocco","year":"2017","journal-title":"Current Treatment Options in Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0464|cit464","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1192\/bjo.2018.64","article-title":"Neuropsychiatric profile and psychotropic medication use in adults with autism spectrum disorder: results from the Australian Longitudinal Study of Adults with Autism","volume":"4","author":"Cvejic","year":"2018","journal-title":"BJPsych Open"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0465|cit465","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3389\/fpsyt.2018.00270","article-title":"Anticonvulsants for psychiatric disorders in children and adolescents: a systematic review of their efficacy","volume":"9","author":"Davico","year":"2018","journal-title":"Frontiers in Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0466|cit466","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.psychres.2019.06.020","article-title":"Efficacy and tolerability of riluzole in psychiatric disorders: a systematic review and preliminary meta-analysis","volume":"278","author":"De Boer","year":"2019","journal-title":"Psychiatry Research"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0467|cit467","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/j.2051-5545.2009.tb00248.x","article-title":"International guide to prescribing psychotropic medication for the management of problem behaviours in adults with intellectual disabilities","volume":"8","author":"Deb","year":"2009","journal-title":"World Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0468|cit468","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/jir.12119","article-title":"Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour","volume":"59","author":"Deb","year":"2015","journal-title":"Journal of Intellectual Disability Research"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0469|cit469","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1192\/bjo.2021.1003","article-title":"Randomised controlled trials of antidepressant and anti-anxiety medications for people with autism spectrum disorder: systematic review and meta-analysis","volume":"7","author":"Deb","year":"2021","journal-title":"BJPsych Open"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0470|cit470","unstructured":"Deeks JJ Higgins JP Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0471|cit471","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.pharmthera.2004.10.004","article-title":"Cellular mechanisms underlying acquired epilepsy: the calcium hypothesis of the induction and maintainance of epilepsy","volume":"105","author":"DeLorenzo","year":"2005","journal-title":"Pharmacology & Therapeutics"},{"issue":"8","key":"10.1002\/14651858.CD011769.pub2-BIB0472|cit472","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1172\/JCI127411","article-title":"Autism-linked dopamine transporter mutation alters striatal dopamine neurotransmission and dopamine dependent behaviors","volume":"129","author":"DiCarlo","year":"2019","journal-title":"Journal of Clinical Investigation"},{"issue":"12","key":"10.1002\/14651858.CD011769.pub2-BIB0473|cit473","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s00787-020-01488-6","article-title":"Prescribing antipsychotics in child and adolescent psychiatry - guideline adherence","volume":"29","author":"Dinnissen","year":"2020","journal-title":"European Child and Adolescent Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0474|cit474","volume-title":"DSM-4. Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0475|cit475","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2000"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0476|cit476","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"DSM-5. Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0477|cit477","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12955-021-01669-0","article-title":"Impact of antipsychotics in children and adolescents with autism spectrum disorder: a systematic review and meta-analysis","volume":"19","author":"D\u2019Al\u00f2","year":"2021","journal-title":"Health and Quality of Life Outcomes"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0478|cit478","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/aur.239","article-title":"Global prevalence of autism and other pervasive developmental disorders","volume":"5","author":"Elsabbagh","year":"2012","journal-title":"Autism Research"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0479|cit479","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1365-2788.1995.tb00543.x","article-title":"The form and function of challenging behaviours","volume":"39","author":"Emerson","year":"1995","journal-title":"Journal of Intellectual Disability Research"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0480|cit480","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0891-4222(00)00061-5","article-title":"The prevalence of challenging behaviours: a total population study","volume":"22","author":"Emerson","year":"2001","journal-title":"Research in Developmental Disabilities"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0481|cit481","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2217\/npy.13.59","article-title":"Changes in the definition of ADHD in DSM-5: subtle but important","volume":"3","author":"Epstein","year":"2013","journal-title":"Neuropsychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0482|cit482","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00213-006-0518-9","article-title":"A retrospective study of memantine in children and adolescents with pervasive developmental disorders","volume":"191","author":"Erickson","year":"2007","journal-title":"Psychopharmacology"},{"issue":"9","key":"10.1002\/14651858.CD011769.pub2-BIB0483|cit483","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s10803-009-0750-3","article-title":"A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disorders","volume":"39","author":"Esbensen","year":"2009","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0484|cit484","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1089\/cap.2018.0115","article-title":"Atypical antipsychotics for irritability in pediatric autism: a systematic review and network meta-analysis","volume":"29","author":"Fallah","year":"2019","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0485|cit485","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.2147\/NDT.S84585","article-title":"Aggression in autism spectrum disorder: presentation and treatment options","volume":"12","author":"Fitzpatrick","year":"2016","journal-title":"Neuropsychiatric Disease and Treatment"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0486|cit486","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S0002-7138(09)60610-5","article-title":"A scale for rating symptoms of patients with the syndrome of autism in real life settings","volume":"25","author":"Freeman","year":"1986","journal-title":"Journal of the American academy of child psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD011769.pub2-BIB0487|cit487","first-page":"21","article-title":"Psychostimulant and non-stimulant agents address the symptoms of ADHD substantial evidence shows","volume":"12","author":"Froehlich","year":"2013","journal-title":"Current Psychiatry"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011769.pub2-BIB0488|cit488","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.1542\/peds.2015-2851K","article-title":"Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis","volume":"137","author":"Fung","year":"2016","journal-title":"Pediatrics"},{"issue":"8","key":"10.1002\/14651858.CD011769.pub2-BIB0489|cit489","first-page":"464","article-title":"Managing seizures: achieving control while minimizing risk","volume":"60","author":"Geiger","year":"2011","journal-title":"Journal of Family Practice"},{"issue":"8","key":"10.1002\/14651858.CD011769.pub2-BIB0490|cit490","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1177\/1087054712443154","article-title":"Atomoxetine for treating ADHD symptoms in autism: a systematic review","volume":"17","author":"Ghanizadeh","year":"2013","journal-title":"Journal of Attention Disorders"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0491|cit491","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.2147\/NDT.S194022","article-title":"The effect of stimulants on irritability in autism comorbid with ADHD: a systematic review","volume":"15","author":"Ghanizadeh","year":"2019","journal-title":"Neuropsychiatric Disease and Treatment"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0492|cit492","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/hbm.23915","article-title":"Structural connectivity of the amygdala in young adults with autism spectrum disorder","volume":"39","author":"Gibbard","year":"2018","journal-title":"Human Brain Mapping"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0493|cit493","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2344\/0003-3006-62.1.31","article-title":"Alpha-2 adrenergic receptor agonists: a review of current clinical applications","volume":"62","author":"Thoms","year":"2015","journal-title":"Anesthesia Progress"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0494|cit494","unstructured":"Glover G Williams R Branford D Avery R Chauhan U Hoghton M Prescribing of psychotropic drugs to people with learning disabilities and\/or autism by general practitioners in England Public Health England 2015"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0495|cit495","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/7854_2017_25","volume-title":"Behavioral Pharmacology of Neuropeptides: Oxytocin","author":"Gottschalk","year":"2017"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0496|cit496","unstructured":"GRADEpro. 3.2 for Windows Brozek J Oxman A Sch\u00fcnemann H McMaster University (developed by Evidence Prime)"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0497|cit497","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.nurt.2010.05.006","article-title":"Autism and oxytocin: new developments in translational approaches to therapeutics","volume":"7","author":"Green","year":"2010","journal-title":"Neurotherapeutics"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0498|cit498","volume-title":"Psychopharmacology of brain injured and mentally retarded patients","author":"Gualtieri","year":"2002"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0499|cit499","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/JCP.0b013e318285680c","article-title":"Managing disruptive and compulsive behaviors in adult with autistic disorder with gabapentin","volume":"33","author":"Guglielmo","year":"2013","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0500|cit500","volume-title":"ECDEU Assessment Manual for Psychopharmacology","year":"1976"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0501|cit501","doi-asserted-by":"publisher","first-page":"303\u20138","DOI":"10.1097\/DBP.0b013e3181739b9d","article-title":"Guanfacine in children with autism and\/or intellectual disabilities","volume":"29","author":"Handen","year":"2008","journal-title":"Journal of Developmental and Behavioral Pediatrics"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0502|cit502","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s10803-012-1677-7","article-title":"Brief report: prevalence of attention deficit\/ hyperactivity disorder among individuals with an autism spectrum disorder","volume":"43","author":"Hanson","year":"2013","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0503|cit503","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1192\/bjp.2020.232","article-title":"Antipsychotic and antidepressant prescribing for 704 297 children and young people with and without intellectual disabilities: record linkage study","volume":"218","author":"Henderson","year":"2020","journal-title":"Brtish Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0504|cit504","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0505|cit505","unstructured":"Higgins JP Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 https:\/\/training.cochrane.org\/handbook\/archive\/v5.1\/"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0506|cit506","doi-asserted-by":"publisher","first-page":"98\u2013110","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0507|cit507","unstructured":"Higgins JP Li T Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0508|cit508","unstructured":"Higgins JP Eldridge S Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook"},{"issue":"9","key":"10.1002\/14651858.CD011769.pub2-BIB0509|cit509","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.rasd.2014.05.006","article-title":"Aggressive behaviour problems in children with autism spectrum disorders: prevalence and correlates in a large clinical sample","volume":"8","author":"Hill","year":"2014","journal-title":"Research in Autism Spectrum Disorders"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0510|cit510","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009043.pub3","article-title":"Aripiprazole for autism spectrum disorders (ASD)","author":"Hirsch","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD011769.pub2-BIB0511|cit511","doi-asserted-by":"publisher","first-page":"530","DOI":"10.4088\/jcp.v62n07a05","article-title":"An open trial of divalproex sodium in autism spectrum disorders","volume":"62","author":"Hollander","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0512|cit512","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1017\/S0033291718002283","article-title":"Anxiety and depression in adults with autism spectrum disorder: a systematic review and meta-analysis","volume":"49","author":"Hollocks","year":"2019","journal-title":"Psychological Medicine"},{"issue":"10","key":"10.1002\/14651858.CD011769.pub2-BIB0513|cit513","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s11892-019-1220-8","article-title":"Association between antipsychotic medication use and diabetes","volume":"19","author":"Holt","year":"2019","journal-title":"Current Diabetes Reports"},{"issue":"12","key":"10.1002\/14651858.CD011769.pub2-BIB0514|cit514","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1002\/aur.1848","article-title":"Psychiatric comorbidities and use of psychotropic medications in people with autism spectrum disorder in the United States","volume":"10","author":"Houghton","year":"2017","journal-title":"Autism Research"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0515|cit515","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0269881117741766","article-title":"Autism spectrum disorder: consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology","volume":"32","author":"Howes","year":"2018","journal-title":"Journal of Psychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD011769.pub2-BIB0516|cit516","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3928\/02793695-20151022-01","article-title":"Buspirone: back to the future","volume":"53","author":"Howland","year":"2015","journal-title":"Journal of Psychosocial Nursing and Mental Health Services"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0517|cit517","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00213-013-3263-x","article-title":"Psychopharmacological prescriptions for people with autism spectrum disorder (ASD): a multinational study","volume":"231","author":"Hsia","year":"2014","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0518|cit518","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008372.pub2","article-title":"Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents","author":"Hurwitz","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0519|cit519","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40261-015-0336-0","article-title":"Guanfacine extended release: a new pharmacological treatment option in Europe","volume":"36","author":"Huss","year":"2016","journal-title":"Clinical Drug Investigation"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0520|cit520","volume-title":"ICD-10: International Classification of Diseases for Mortality and Morbidity Statistics","author":"World Health Organization","year":"2004"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0521|cit521","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/npp.2011.281","article-title":"Compound stimulus presentation and the norepinephrine reuptake inhibitor atomoxetine enhance long-term extinction of cocaine-seeking behavior","volume":"37","author":"Janak","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0522|cit522","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005040.pub2","article-title":"Risperidone for autism spectrum disorder","author":"Jesner","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD011769.pub2-BIB0523|cit523","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1177\/13623613211034375","article-title":"Oxytocin levels tend to be lower in autistic children: a meta-analysis of 31 studies","volume":"25","author":"John","year":"2021","journal-title":"Autism"},{"issue":"11","key":"10.1002\/14651858.CD011769.pub2-BIB0524|cit524","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1586\/14737175.2015.1111762","article-title":"Anxiety in youth with autism spectrum disorders implications for treatment","volume":"15","author":"Johnco","year":"2015","journal-title":"Expert Review of Neurotherapeutics"},{"issue":"7","key":"10.1002\/14651858.CD011769.pub2-BIB0525|cit525","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1007\/s10803-010-1118-4","article-title":"Aggression in children and adolescents with ASD: prevalence and risk factors","volume":"41","author":"Kanne","year":"2011","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0526|cit526","doi-asserted-by":"publisher","first-page":"658\u201365","DOI":"10.1097\/00004583-200106000-00010","article-title":"Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder","volume":"40","author":"King","year":"2001","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0527|cit527","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1108\/AMHID-06-2015-0029","article-title":"Predictors of challenging behaviour in adults with intellectual disability","volume":"9","author":"Koritsas","year":"2015","journal-title":"Advances in Mental Health and Intllectual Disabilities"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0528|cit528","doi-asserted-by":"publisher","first-page":"e1322","DOI":"10.1542\/peds.2011-0428","article-title":"A systematic review of secretin for children with autism spectrum disorders","volume":"127","author":"Krishnaswami","year":"2011","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0529|cit529","doi-asserted-by":"crossref","unstructured":"Kusmaker S Karmaker CK Yan B O'Brien TJ Mathuganapathy R Palaniswarmi M Onset detection of epileptic seizures from acceloerometry signal 40th Annual Internal Conference of the IEEE Engineering in Medicine and Biology Society (EMBC); 2018 Jul 18-12; Honolulu (HI), USA 2018 1 4 10.1109\/EMBC.2018.8513669","DOI":"10.1109\/EMBC.2018.8513669"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0530|cit530","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s10803-017-3058-8","article-title":"Medical conditions and demographic, service and clinical factors associated with atypical antipsychotic medication use among children with an autism spectrum disorder","volume":"47","author":"Lake","year":"2017","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0531|cit531","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1177\/0004867420952540","article-title":"Effectiveness of N-acetylcysteine in autism spectrum disorders: a meta-analysis of randomized controlled trials","volume":"55","year":"2021","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0532|cit532","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jaac.2017.03.013","article-title":"What is the male-to-female ratio in autism spectrum disorder? A systematic review and meta-analysis","volume":"56","author":"Loomes","year":"2017","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0533|cit533","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/BF021172145","article-title":"Autism Diagnostic Interview Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders","volume":"24","author":"Lord","year":"1994","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0534|cit534","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1023\/A:1005592401947","article-title":"Autism Diagnostic Interview Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders","volume":"30","author":"Lord","year":"2000","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"10146","key":"10.1002\/14651858.CD011769.pub2-BIB0535|cit535","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/S0140-6736(18)31129-2","article-title":"Autism Spectrum Disorder","volume":"392","author":"Lord","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD011769.pub2-BIB0536|cit536","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008559.pub3","article-title":"Atypical antipsychotics for disruptive behaviour disorders in children and youths","author":"Loy","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0537|cit537","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s10803-016-2946-7","article-title":"Psychotropic medication use among insured children with autism spectrum disorder","volume":"47","author":"Madden","year":"2017","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0538|cit538","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.2147\/NDT.S174622","article-title":"Aripiprazole in acute treatment of children and adolescents with autism spectrum disorder: a systematic review and meta-analysis","volume":"14","author":"Maneeton","year":"2018","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0539|cit539","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.2147\/NDT.S151802","article-title":"Risperidone for children and adolescents with autism spectrum disorder: a systematic review","volume":"14","author":"Maneeton","year":"2018","journal-title":"Neuropsychiatric Disease and Treatment"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0540|cit540","doi-asserted-by":"publisher","first-page":"538","DOI":"10.2174\/1570159X18666200529151741","article-title":"Effects of risperidone in autistic children and young adults: a systematic review and meta-analysis","volume":"19","author":"Mano-Sousa","year":"2021","journal-title":"Current Neuropharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0541|cit541","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1080\/00207454.2017.1385614","article-title":"The dopaminergic system dynamic in the time perception: a review of the evidence","volume":"128","author":"Marinho","year":"2018","journal-title":"International Journal of Neuroscience"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0542|cit542","doi-asserted-by":"publisher","first-page":"959","DOI":"10.2147\/CLEP.S373186","article-title":"Autism spectrum disorder diagnoses: a comparison of countries with different income levels","volume":"14","author":"Matos","journal-title":"Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0543|cit543","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1468-3148.2008.00477.x","article-title":"Restraint procedures and challenging behaviours in intellectual disability: an analysis of causative factors","volume":"22","author":"Matson","year":"2009","journal-title":"Journal of Applied Research in Intellectual Disabilities"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0544|cit544","doi-asserted-by":"publisher","first-page":"e015549","DOI":"10.1136\/bmjopen-2016-015549","article-title":"Autism spectrum disorder: updated prevalence and comparison of two birth cohorts in a nationally representative Australian sample","volume":"7","author":"May","year":"2017","journal-title":"BMJ Open"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0545|cit545","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/aur.2286","article-title":"Autism spectrum disorder prevalence in children aged 12-13 years from the Longitudinal Study of Australian Children","volume":"13","author":"May","year":"2020","journal-title":"Autism Research"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0546|cit546","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1345\/aph.19113","article-title":"Secretin for the treatment of autism","volume":"36","author":"McQueen","year":"2002","journal-title":"Annals of Pharmacotherapy"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0547|cit547","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.rasd.2011.01.009","article-title":"Analysis of risk factors and early predictors of challenging behavior for children with autism spectrum disorder","volume":"5","author":"McTiernan","year":"2011","journal-title":"Research in Autism Spectrum Disorders"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0548|cit548","doi-asserted-by":"publisher","first-page":"107940","DOI":"10.1016\/j.pharmthera.2021.107940","article-title":"Evidence-based pharmacological treatment options for ADHD in children and adolescents","volume":"230","author":"Mechler","year":"2022","journal-title":"Pharmacology & therapeutics"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0549|cit549","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.cpr.2018.12.005","article-title":"Social functioning in youth with attention-deficit\/hyperactivity disorder and autism spectrum disorder: transdiagnostic commonalities and differences","volume":"68","author":"Mikami","year":"2019","journal-title":"Clinical Psychology Review"},{"issue":"7","key":"10.1002\/14651858.CD011769.pub2-BIB0550|cit550","doi-asserted-by":"publisher","first-page":"454\u201360","DOI":"10.1016\/j.braindev.2007.12.007","article-title":"Use of clonidine in children with autism spectrum disorders","volume":"30","author":"Ming","year":"2008","journal-title":"Brain & Development"},{"issue":"11","key":"10.1002\/14651858.CD011769.pub2-BIB0551|cit551","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.3390\/brainsci11111545","article-title":"Endogenous oxytocin levels in autism\u2014a meta-analysis","volume":"11","author":"Moerkerke","year":"2021","journal-title":"Brain Sciences"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0552|cit552","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0553|cit553","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s00213-013-3140-7","article-title":"Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care","volume":"231","author":"Murray","year":"2014","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0554|cit554","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/2047-9158-1-10","article-title":"Drug therapy in patients with Parkinson\u2019s disease","volume":"1","author":"M\u00fcller","year":"2012","journal-title":"Translational Neurodegeneration"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0555|cit555","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2217\/npy.11.62","article-title":"Treatment of comorbid anxiety and autism spectrum disorders","volume":"1","author":"Nadeau","year":"2011","journal-title":"Neuropsychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0556|cit556","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1001\/archgenpsychiatry.2009.137","article-title":"Brain serotonin and dopamine transporter bindings in adults with high-functioning autism","volume":"67","author":"Nakamura","year":"2010","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0557|cit557","unstructured":"National Autistic Society How to talk and write about autism https:\/\/www.autism.org.uk\/what-we-do\/help-and-support\/how-to-talk-about-autism"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0558|cit558","unstructured":"National Institute for Health and Care Excellence Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges. NICE guideline (NG11); May 2015 Available at www.nice.org.uk\/guidance\/ng11"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0559|cit559","doi-asserted-by":"publisher","first-page":"746","DOI":"10.2174\/156720512801322564","article-title":"N-Methyl D-Aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia, and Parkinson's disease","volume":"9","author":"Olivares","year":"2012","journal-title":"Current Alzheimer Research"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0560|cit560","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/0891-4222(96)00015-7","article-title":"Factor validity and reliability for the Aberrant Behavior Checklist-Community in a Japanese population with mental retardation","volume":"17","author":"Ono","year":"1996","journal-title":"Research in Developmental Disabilities"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0561|cit561","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1055\/s-0042-109400","article-title":"Oxytocin and autism spectrum disorders: a systematic review and meta-analysis of randomized controlled trials","volume":"50","author":"Ooi","year":"2017","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0562|cit562","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007990.pub3","article-title":"Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders","author":"Osland","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD011769.pub2-BIB0563|cit563","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.3390\/ijms23084420","article-title":"Anti-inflammatory and neuroprotective mechanisms of GTS-21, an \u03b17 nicotinic acetylcholine receptor agonist, in neuroinflammation and Parkinson\u2019s disease mouse models","volume":"23","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0564|cit564","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/aur.2059","article-title":"Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: a systematic review and meta-analysis","volume":"12","author":"Patra","year":"2019","journal-title":"Autism Research"},{"issue":"7","key":"10.1002\/14651858.CD011769.pub2-BIB0565|cit565","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/aur.2765","article-title":"Diagnosing autism in low-income countries: clinical record-based analysis in Sri Lanka","volume":"15","author":"Peiris","year":"2022","journal-title":"Autism Research"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0566|cit566","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1440-1630.2012.01036.x","article-title":"Contribution of occupational therapists in positive behaviour support","volume":"59","author":"Perez","year":"2012","journal-title":"Australian Occupational Therapy Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011769.pub2-BIB0567|cit567","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1080\/15622975.2018.1468030","article-title":"Anxiolytics targeting GABAA receptors: insights on etifoxine","volume":"19","author":"Poisbeau","year":"2018","journal-title":"World Journal of Biological Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0568|cit568","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1517\/14656566.2.4.587","article-title":"Pharmacotherapeutic management of autism","volume":"2","author":"Posey","year":"2001","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0569|cit569","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.mehy.2006.06.041","article-title":"Prenatal influences on brain dopamine and their relevance to the rising incidence of autism","volume":"68","author":"Previc","year":"2007","journal-title":"Medical Hypotheses"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0570|cit570","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41467-018-02973-y","article-title":"Predicting the spatiotemporal diversity of seizure propagation and termination in human focal epilepsy","volume":"9","author":"Proix","year":"2018","journal-title":"Nature Communications"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0571|cit571","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fncel.2020.00073","article-title":"The potential role of gut peptide hormones in autism spectrum disorder","volume":"14","author":"Zhang","year":"2020","journal-title":"Frontiers in Cellular Neuroscience"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0572|cit572","unstructured":"Ramcharan P Nankervis K Strong M Robertson A Experiences of restrictive practices: a view from people with disabilities and family carers. A final research report to the office of the Senior Practitioner; May 2009 Available at vgls.sdp.sirsidynix.net.au\/client\/search\/asset\/1297931"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0573|cit573","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10803-018-3718-3","article-title":"Prevalence of psychotropic medicine use in Australian children with autism spectrum disorder: a drug utilization study based on children enrolled in the longitudinal study of Australian children","volume":"49","author":"Rasmussen","year":"2019","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0574|cit574","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2021"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0575|cit575","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s12640-013-9393-4","article-title":"Altered cytokine and BDNF levels in autism spectrum disorder","volume":"24","author":"Ricci","year":"2013","journal-title":"Neurotoxicity Research"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0576|cit576","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1080\/1034912X.2019.1596228","article-title":"Managing children with challenging behaviours. Parents' meaning-making processes in relation to their children's ADHD diagnosis","volume":"67","author":"Ringer","year":"2020","journal-title":"International journal of disability, development and education"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0577|cit577","unstructured":"Ritchie H Neurodevelopmental disorders www.ourworldindata.org\/neurodevelopmental-disorders"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0578|cit578","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1023\/A:1013299028321","article-title":"The behaviour problems inventory - an instrument for the assessment of self-injury, stereotyped behaviour, and aggression\/destruction in individuals with developmental disabilities","volume":"31","author":"Rojahn","year":"2001","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"8","key":"10.1002\/14651858.CD011769.pub2-BIB0579|cit579","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00702-014-1216-0","article-title":"The role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment","volume":"121","author":"Rojas","year":"2014","journal-title":"Journal of Neural Transmission"},{"issue":"11","key":"10.1002\/14651858.CD011769.pub2-BIB0580|cit580","doi-asserted-by":"publisher","first-page":"e0207286","DOI":"10.1371\/journal.pone.0207286","article-title":"ADHD symptoms and learning behaviors in children with ASD without intellectual disability. A mediation analysis of executive functions","volume":"13","author":"Rosello","year":"2018","journal-title":"PloS one"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011769.pub2-BIB0581|cit581","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00259-007-0701-1","article-title":"Acetylcholine receptors in dementia and mild cognitive impairment","volume":"35","author":"Sabri","year":"2008","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"35","key":"10.1002\/14651858.CD011769.pub2-BIB0582|cit582","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta16350","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies","volume":"16","author":"Savovi\u0107","year":"2012","journal-title":"Health Technology Assessment"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0583|cit583","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1001\/jamapediatrics.2015.3935","article-title":"Association of psychiatric and neurologic comorbidity with mortality among persons with autism spectrum disorder in a Danish population","volume":"170","author":"Schendel","year":"2016","journal-title":"JAMA Pediatrics"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0584|cit584","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1590\/S1516-44462005000100007","article-title":"The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta-analysis","volume":"27","author":"Schmitt","year":"2005","journal-title":"Revista Brasileira de Psiquiatria"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0585|cit585","unstructured":"Schopler E Van Bourgondien ME Wellman J Love S Childhood Autism Rating Scale-second edition (CARS2): Manual Childhood Autism Rating Scale, Second Edition (CARS-2) | Pearson Clinical Australia & New Zealand 2009"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0586|cit586","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0587|cit587","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0588|cit588","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1469-8749.2008.03211.x","article-title":"Systematic reviews of psychosocial interventions for autism: an umbrella review","volume":"51","author":"Seida","year":"2009","journal-title":"Developmental Medicine and Child Neurology"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0589|cit589","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s12098-015-1967-0","article-title":"Educational and behavioral interventions in management of autism spectrum disorder","volume":"84","author":"Sengupta","year":"2017","journal-title":"Indian Journal of Pediatrics"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0590|cit590","doi-asserted-by":"publisher","first-page":"h4326","DOI":"10.1136\/bmj.h4326","article-title":"Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study","volume":"351","author":"Sheehan","year":"2015","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0591|cit591","doi-asserted-by":"publisher","first-page":"447","DOI":"10.33945\/SAMI\/CHEMM.2020.4.7","article-title":"Quantum computations of interactions of most reactive tricyclic antidepressant drug with carbon nanotube, serotonin, and norepinephrin","volume":"4","author":"Shojaie","year":"2020","journal-title":"Chemical Methodologies"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0592|cit592","unstructured":"Scottish Intercollegiate Guidelines Network SIGN145. Assessment, diagnosis and interventions for autism spectrum disorders: a national clinical guideline; June 2016 Available at www.sign.ac.uk\/assets\/sign145.pdf"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0593|cit593","doi-asserted-by":"publisher","first-page":"JC12","DOI":"10.7326\/ACPJC-2015-162-4-012","article-title":"ACP Journal Club: new use of atypical antipsychotics was linked to acute kidney injury and all-cause mortality at 90 days","volume":"162","author":"Simon","year":"2015","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0594|cit594","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.chc.2013.08.006","article-title":"The family context of autism spectrum disorders: influence on the behavioral phenotype and quality of life","volume":"23","author":"Smith","year":"2014","journal-title":"Child and Adolescent Psychiatric Clinics of North America"},{"issue":"11","key":"10.1002\/14651858.CD011769.pub2-BIB0595|cit595","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1007\/s10803-016-2879-1","article-title":"Brief report: prevalence of self-injurious behaviors among children with autism spectrum disorder\u2014a population-based study","volume":"46","author":"Soke","year":"2016","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"6","key":"10.1002\/14651858.CD011769.pub2-BIB0596|cit596","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s10803-017-3083-7","article-title":"A causal and mediation analysis of the comorbidity between attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD)","volume":"47","author":"Sokolova","year":"2017","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0597|cit597","unstructured":"Stata StataCorp 2013"},{"issue":"11","key":"10.1002\/14651858.CD011769.pub2-BIB0598|cit598","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011144.pub2","article-title":"Methylphenidate for children and adolescents with autism spectrum disorder","author":"Sturman","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0599|cit599","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1021\/acs.molpharmaceut.7b00991","article-title":"Delivery of oxytocin to the brain for the treatment of autism spectrum disorder by nasal application","volume":"15","author":"Tanaka","year":"2018","journal-title":"Molecular Pharmaceutics"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0600|cit600","volume-title":"Autism Spectrum Disorders through the Life Span","author":"Tantam","year":"2012"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0601|cit601","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1124\/jpet.118.250852","article-title":"Binding characteristics of two oxytocin variants and vasopressin at oxytocin receptors from four primate species with different social behaviour patterns","volume":"367","author":"Taylor","year":"2018","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0602|cit602","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.cpr.2017.01.009","article-title":"Defining and measuring irritability: construct clarification and differentiation","volume":"53","author":"Toohey","year":"2017","journal-title":"Clinical Psychology Review"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0603|cit603","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2008.09.017","article-title":"Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile?","volume":"59","author":"Trifir\u00f2","year":"2009","journal-title":"Pharmacological Research"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0604|cit604","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10803-012-1617-6","article-title":"Prevalence of psychotropic drug use in adults with intellectual disability: positive and negative findings from a large scale study","volume":"43","author":"Tsouris","year":"2013","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0605|cit605","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1093\/ije\/dys041","article-title":"Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews","volume":"41","author":"Turner","year":"2012","journal-title":"International Journal of Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0606|cit606","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/1467-9566.12382","article-title":"Category attribution as a device for diagnosis: fitting children to the autism spectrum","volume":"38","author":"Turowetz","year":"2015","journal-title":"Sociology of Health & Illness"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0607|cit607","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1365-2788.2005.00774.x","article-title":"Physical aggression towards others in adults with learning disabilities: prevalence and associated factors","volume":"50","author":"Tyrer","year":"2006","journal-title":"Journal of Intellectual Disability Research"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0608|cit608","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41398-019-0619-y","article-title":"Adult attention-deficit\/hyperactivity disorder is associated with reduced norepinephrine transporter availability in right attention networks: a (S,S)-O-[11C]methylreboxetine positron emission tomography study","volume":"9","author":"Ulke","year":"2019","journal-title":"Translational Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0609|cit609","doi-asserted-by":"publisher","first-page":"744597","DOI":"10.3389\/fnmol.2021.744597","article-title":"Dysregulation of neuronal nicotinic acetylcholine receptor - cholesterol crosstalk in autism spectrum disorder","volume":"14","author":"Vall\u00e9s","year":"2021","journal-title":"Frontiers in Molecular Neuroscience"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0610|cit610","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s10567-011-0097-0","article-title":"Anxiety disorders in children and adolescents with autistic spectrum disorders: a meta-analysis","volume":"14","author":"Van Steensel","year":"2011","journal-title":"Clinical Child and Family Psychology Review"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0611|cit611","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/00005650-199902000-00003","article-title":"The PedsQL - measurement model for the pediatric quality of life inventory","volume":"37","author":"Varni","year":"1999","journal-title":"Medical care"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0612|cit612","unstructured":"Varni JW The PedsQL measurement model for the pediatric quality of life inventory https:\/\/www.pedsql.org\/index.html"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0613|cit613","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/npp.2011.185","article-title":"Networking in autism: leveraging genetic, biomarker, and model system findings in the search for new treatments","volume":"37","author":"Veenstra-VanderWeele","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0614|cit614","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clineuro.2009.10.011","article-title":"Bone and calcium metabolism and antiepileptic drugs","volume":"112","author":"Verrotti","year":"2010","journal-title":"Clinical Neurology and Neurosurgery"},{"issue":"8","key":"10.1002\/14651858.CD011769.pub2-BIB0615|cit615","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1177\/1362361316665222","article-title":"Comorbidity prevalence, healthcare utilization, and expenditures of Medicaid enrolled adults with autism spectrum disorders","volume":"21","author":"Vohra","year":"2017","journal-title":"Autism"},{"issue":"11","key":"10.1002\/14651858.CD011769.pub2-BIB0616|cit616","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1007\/s00415-013-7058-0","article-title":"Treatment of epilepsy in daily clinical practice: have outcomes improved over the past 10 years?","volume":"260","author":"Wassenaar","year":"2013","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0617|cit617","volume-title":"Therapies for Children with Autism Spectrum Disorder: Behavioral Interventions Update","author":"Weitlauf","year":"2014"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0618|cit618","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1023\/B:CEMN.0000018618.59015.a2","article-title":"Secretin: hypothalamic distribution and hypothesized neuroregulatory role in autism","volume":"24","author":"Welch","year":"2004","journal-title":"Cellular and Molecular Neurobiology"},{"issue":"2","key":"10.1002\/14651858.CD011769.pub2-BIB0619|cit619","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression","volume":"3","author":"White","year":"2012","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0620|cit620","unstructured":"World Health Organization WHO Quality of Life user manual file:\/\/\/U:\/Downloads\/WHO_HIS_HSI_Rev.2012.03_eng%20(1).pdf 1998"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0621|cit621","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.2147\/NDT.S207580","article-title":"Differences on oxytocin and vasopressin levels in individuals suffering from the autism spectrum disorders vs general population \u2013 a systematic review","volume":"15","author":"Wilczy\u0144ski","year":"2019","journal-title":"Neuropsychiatric Disease and Treatment"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0622|cit622","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003495.pub3","article-title":"Intravenous secretin for autism spectrum disorders (ASD)","author":"Williams","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD011769.pub2-BIB0623|cit623","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004677.pub3","article-title":"Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)","author":"Williams","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD011769.pub2-BIB0624|cit624","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1002\/ajmg.a.35438","article-title":"Antiepileptic drugs and pregnancy outcomes","volume":"158A","author":"Wlodarczyk","year":"2012","journal-title":"American Journal of Medical Genetics. Part A"},{"issue":"3","key":"10.1002\/14651858.CD011769.pub2-BIB0625|cit625","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s12035-012-8278-5","article-title":"Role of dopamine receptors in ADHD: a systematic meta-analysis","volume":"45","author":"Wu","year":"2012","journal-title":"Molecular Neurobiology"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0626|cit626","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/7854_2017_24","volume-title":"Behavioral Pharmacology of Neuropeptides: Oxytocin","author":"Yamasue","year":"2017"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0627|cit627","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/978-981-32-9705-07","volume-title":"Anxiety Disorders: Rethinking and Understanding Recent Discoveries. Advances in Experimental Medicine and Biology","volume":"1191","author":"Yoon","year":"2020"},{"issue":"4","key":"10.1002\/14651858.CD011769.pub2-BIB0628|cit628","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/s0091-3057(01)00670-0","article-title":"The role of serotonin in human mood and social interaction: insight from altered tryptophan levels","volume":"71","author":"Young","year":"2002","journal-title":"Pharmacology, Biochemistry and Behavior"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0629|cit629","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1176\/ajp.143.1.35","article-title":"The Overt Aggression Scale for the objective rating of verbal and physical aggression","volume":"143","author":"Yudofsky","year":"2003","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0630|cit630","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2217\/fnl-2017-0030","article-title":"Comorbid autism spectrum disorder and anxiety disorders: a brief review","volume":"13","author":"Zaboski","year":"2018","journal-title":"Future Neurology"},{"issue":"5","key":"10.1002\/14651858.CD011769.pub2-BIB0631|cit631","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/aur.2696","article-title":"Global prevalence of autism: a sysyematic review update","volume":"15","author":"Zeidan","journal-title":"Autism Research"},{"issue":"1","key":"10.1002\/14651858.CD011769.pub2-BIB0632|cit632","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12888-019-2177-5","article-title":"Antipsychotic drug use and risk of stroke and myocardial infarction: a systematic review and meta-analysis","volume":"19","author":"Zivkovic","year":"2019","journal-title":"BMC Psychiatry"},{"key":"10.1002\/14651858.CD011769.pub2-BIB0633|cit633","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.lfs.2018.08.050","article-title":"Serotonin receptors in depression and anxiety: insights from animal studies","volume":"210","author":"\u017bmudzka","year":"2018","journal-title":"Life Sciences"},{"issue":"7","key":"10.1002\/14651858.CD011769.pub2-BIB0634|cit634","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011769","article-title":"Pharmacological intervention for irritability, aggression, and self-injury in Autism Spectrum Disorders (ASD)","author":"Livingstone","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T02:23:06Z","timestamp":1760494986000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011769.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Developmental, Psychosocial and Learning Problems Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":634,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011769.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,9]]}}}